Patent US5672605A successfully refreshed from Google Patents.
US5672605A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Macrolide immunomodulators
Assignee: Abbott Laboratories
•
Filing: 1995-04-19
•
Granted: 1997-09-30
•
Expires: 2015-04-19
Abstract
Abstract Novel macrolide compounds of the formula <IMAGE> and pharmaceutically acceptable salts, esters, amides and prodrugs thereof, processes for the preparation of the compounds of the invention, intermediates useful in these processes, a pharmaceutical composition, and a method of treating immunomodulatory disorders are disclosed.
Inventors
- 👤 Yat Sun Or
- 👤 Jay R. Luly
- 👤 Rolf Wagner
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-08 23:14
CPC Classifications
C; C07; C07D; C07D498/00; C07D498/12; C07D498/18; A; A61; A61P; A61P37/00; A61P37/02; A61P37/06
Claims Analysis
Total Claims: 12
Claim 1
Independent Claim
1530 words
A method of immunomodulatory treatment comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compound having the formula: ##STR20## or a pharmaceutically acceptable salt, ester, amide or prodrug thereof wherein R 1 is hydrogen, a hydroxy protecting group, C 1 -C 10 -loweralkyl or phenyl-substituted C 1 -C 10 -loweralkyl; R 2 is hydrogen and R 3 is hydroxy or protected hydroxy or R 2 and R 3 taken together are oxo; R 4 is hydrogen or phenyl-substituted C 1 -C 10 loweralkyl and R 5 is hydroxy or protected hydroxy or R 5 is hydrogen or phenyl-substituted C 1 -C 10 -loweralkyl and R 4 is hydroxy or protected hydroxy or R 4 and R 5 taken together are oxo; R 6 is hydrogen or phenyl-substituted C 1 -C 10 -loweralkyl and R 7 is hydrogen, hydroxy or protected hydroxy or R 7 is hydrogen or phenyl-substituted C 1 -C 10 -loweralkyl and R 6 is hydroxy or protected hydroxy or R 6 and R 7 taken together are (1) oxo, (2) diazo, (3) ═CH 2 (4) --O--(CH 2 ) 2 --O--, (5) --S--(CH 2 ) 2 --S--, (6) --O--(CH 2 ) 3 --O--, (7) --S--(CH 2 ) 3 --S--, (8) ═N--OR 20 wherein R 20 is hydrogen, C 1 -C 10 -loweralkyl, C 2 -C 10 -alkenyl, C 3 -C 10 -cycloalkyl, C 3 -C 10 -cycloalkenyl, C 3 -C 10 -bicycloalkenyl, aryl, aryl-C 1 -C 10 -alkyl, heterocyclic or heterocyclic-C 1 -C 10 -alkyl, each of which is optionally substituted with C 1 -C 10 -loweralkyl, halogen, hydroxy, aryl or heterocyclic; or (9) ═N--N(R 21 )(R 22 ) wherein R 21 and R 22 are independently selected from hydrogen, C 1 -C 10 -loweralkyl, aryl, aryl-C 1 -C 10 -alkyl, heterocyclic and heterocyclic-C 1 -C 10 -alkyl; R 8 is hydrogen; R 9 is (1) --OS(O) 2 CF 3 , (2) --OS(O) 2 F, (3) --OS(O) 2 R 21a wherein R 21a is C 1 -C 10 -loweralkyl, aryl, aryl-C 1 -C 10 -alkyl, heterocyclic or heterocyclic-C 1 -C 10 -alkyl, (4) --OC(O)R 23 wherein R 23 is C 1 -C 10 -loweralkyl, C 3 -C 10 -cycloalkyl, C 3 -C 10 -cycloalkyl-C 1 -C 10 -alkyl, aryl, aryl-C 1 -C 10 -alkyl, heterocyclic, heterocyclic-C 1 -C 10 -alkyl, alkoxy, --O--C 3 -C 10 -cycloalkyl, --O-aryl, --O-heterocyclic, --O--(N-succinimidyl) or 5-tetrazolyl; (5) --OC(O)--N(R 24 )(R 25 ) wherein R 24 and R 25 are independently selected from (a) hydrogen, (b) C 1 -C 10 -loweralkyl, (c) C 2 -C 10 -alkenyl, (d) C 2 -C 10 -alkynyl, (e) C 3 -C 10 -cycloalkyl, (f) substituted C 1 -C 10 -loweralkyl, substituted C 2 -C 10 -alkenyl, substituted C 2 -C 10 -alkynyl or substituted C 3 -C 10 -cycloalkyl wherein the C 1 -C 10 -loweralkyl group, the C 2 -C 10 -alkenyl group, the C 2 -C 10 -alkynyl group or the C 3 -C 10 -cycloalkyl group is substituted by one or two substituents independently selected from (i) hydroxy, (ii) --COOH, (iii) --CN, (iv) --Q--C 1 -C 10 -loweralkyl, --Q-aryl, --Q-(aryl-C 1 -C 10 -alkyl), --Q-heterocyclic or --Q-(heterocyclicalkyl) wherein Q is --O--, --S--, --S(O)--, --S(O) 2 --, --C(O)--, --OC(O)--, --C(O)O--, --C(O)C(O)--O--, --O--C(O)C(O)--, --C(O)NH--, --NHC(O)--, --OC(O)NH--, --NHC(O)O--, --NH--C(O)--NH--, --S(O) 2 NH--, --NHS(O) 2 --, --N(R 27 )--, --C(NR 27 )NHNH-- and --NHNHC(NR 27 )-- wherein R 27 is hydrogen, C 1 -C 10 -loweralkyl, aryl or heterocyclic, (v) C 3 -C 10 -cycloalkyl, (vi) aryl, (vii) heterocyclic, (viii) --N(R 28 )(R 29 ) wherein R 28 and R 29 are independently selected from hydrogen, C 1 -C 10 -loweralkyl, hydroxy-C 1 -C 10 -alkyl, aryl and heterocyclic, (ix) guanidino, (x) --S(O) 2 R 11 wherein R 11 is C 1 -C 10 -loweralkyl, aryl or aryl-C 1 -C 10 -alkyl, (xi) --OS(O) 2 R 11 wherein R 11 is defined as above, (xii) --SO 3 H, (xiii) --S(O) 2 NH 2 , (xiv) --SR 28 wherein R 28 is defined as above, (xv) halogen, (xvi) oxo and (xvii) epoxy; (g) aryl, (h) heterocyclic, (i) --NHC(O)--O--(C 1 -C 10 -loweralkyl), (j) --NHC(O)-aryl, (k) --NHC(O)-heterocyclic and (l) C 1 -C 10 -loweralkyl substituted by --OC(O)--R f wherein R f is carboxy-C 3 -C 10 -alkyl or --N(R 24 )(R 25 ) taken together form a nitrogen-containing heterocyclic group, (6) --OR 25 wherein R 25 is as defined above, (7) a protected hydroxy group, (8) --OC(O)N(OR 24 )(R 25 ) wherein R 24 and R 25 are defined as above, (9) --O(CH 2 ) i C(O)OR 20 wherein i is one or two and R 20 is independently defined as above, (10) --O(CH(Si(CH 3 ) 3 ))-(CH 2 ) j C(O)OR 20 wherein j is zero or one and R 20 is independently defined as above, (11) --O(CH 2 ) i C(O)N(R 24 )(R 25 ) wherein i, R 24 and R 25 are defined as above, (12) --O(CH 2 ) i C(O)N(OR 24 )(R 25 ) wherein i, R 24 and R 25 are defined as above, (13) --O(CH 2 ) i C(O)N(R 24 )(N(R 24 )(R 25 )) wherein i, R 24 and R 25 are defined as above, (14) --O(CH 2 ) i NHC(O)N(R 24 )(R 25 ) wherein i, R 24 and R 25 are defined as above, (15) --O(CH 2 ) i NHC(O)N(OR 24 )(R 25 ) wherein i, R 24 and R 25 are defined as above, (16) --O(CH 2 ) i NHC(O)N(R 24 )(N(R 24 )(R 25 )) wherein i, R 24 and R 25 are defined as above, (17) --OS(O) 2 N(R 24 )(R 25 ) wherein R 24 and R 25 are defined as above, (18) --O(CH 2 ) i --NHC(O)R 24 wherein R 24 is defined as above, (19) --OCH(R 24 )--SH wherein R 24 is defined as above, (20) --OCH(R 24 )--S--C 1 -C 10 -loweralkyl wherein R 24 is defined as above, (21) --OCH(R 24 )--S-aryl wherein R 24 is defined as above and (22) --N 3 ; R 10a is hydrogen and R 10b is hydrogen, hydroxy, protected hydroxy, C 1 -C 10 -alkoxy, C 2 -C 10 -alkenyl, C 2 -C 10 -alkenyloxy, halogen or --SR 28 wherein R 28 is independently defined as above or R 10b is hydrogen and R 10a is hydrogen, hydroxy, protected hydroxy, C 1 -C 10 -alkoxy, C 2 -C 10 -alkenyl, C 2 -C 10 -alkenyloxy, halogen or --SR 28 wherein R 28 is independently defined as above or R 10a and R 10b are both C 1 -C 10 -alkoxy or --SR 28a wherein R 28a is C 1 -C 10 -loweralkyl, aryl or heterocyclic or R 10a and R 10b taken together are oxo; and X is hydrogen and Y is hydrogen, hydroxy or protected hydroxy or Y is hydrogen and X is hydroxy or protected hydroxy or X and Y taken together are oxo wherein at each occurrence the term "aryl" is independently selected from phenyl, naphthyl, fluorenyl, (1,2,3,4-)-tetrahydronaphthyl, indenyl and indanyl which is either unsubstituted or substituted with one, two, or three substituents independently selected from the group consisting of C 1 -C 10 -loweralkyl, halo, halo-C 1 -C 10 -loweralkyl, halo-C 1 -C 10 -alkoxy, C 2 -C 10 -alkenyloxy, C 1 -C 10 -alkoxy, alkoxy-C 1 -C 10 -alkoxy, C 1 -C 10 -alkoxycarbonyl, C 1 -C 10 -alkoxycarbonylalkenyl, (C 1 -C 10 -alkoxycarbonyl)thio-C 1 -C 10 -alkoxy, thio-C 1 -C 10 -alkoxy, amino, C 1 -C 10 -alkylamino, C 1 -C 10 -dialkylamino, aminocarbonyl, aminocarbonyl-C 1 -C 10 -alkoxy, alkanoylamino, aryl-C 1 -C 10 -alkoxy, aryloxy, mercapto, nitro, carboxaldehyde, carboxy, carboxy-C 2 -C 10 -alkenyl, carboxy-C 1 -C 10 -alkoxy, C 1 -C 10 -alkylsulfonylamino, cyano-C 1 -C 10 -alkoxy, (heterocyclic)-C 1 -C 10 -alkoxy, hydroxy, hydroxy-C 1 -C 10 -alkoxy, phenyl, phenyl-substituted C 2 -C 10 -alkenyl, phenyl-substituted C 2 -C 10 -alkynyl, heterocyclic, --S(O) 2 NH 2 , tetrazolyl-C 1 -C 10 -alkoxy, tetrafluorophenyl and pentafluorophenyl and at each occurrence the term "heterocyclic" is independently selected from indolyl, quinolyl, isoquinolyl, tetrahydroquinolyl, benzofuryl, dihydrobenzofuryl, benzothienyl, azetidinyl, oxetanyl, pyrrolyl, pyrrolinyl, pyrrolidinyl, pyrazolyl, pyrazolinyl, pyrazolidinyl, imidazolyl, imidazolinyl, imidazolidinyl, pyridyl, piperidinyl, homopiperidinyl, pyrazinyl, piperazinyl, pyrimidinyl, pyridazinyl, oxazolyl, oxazolidinyl, isoxazolyl, isoxazolidinyl, morpholinyl, thiomorpholinyl, thiazolyl, thiazolidinyl, isothiazolyl, isothiazolidinyl, indolyl, quinolinyl, isoquinolinyl, benzimidazolyl, benzothiazolyl, benzoxazolyl, furyl, thienyl, thiazolidinyl, isothiazolyl, triazolyl, tetrazolyl, isoxazolyl, oxadiazolyl, thiadiazolyl, pyrrolyl, pyrimidyl, benzothienyl, compounds of the formula ##STR21## where X* is --CH 2 -- or --O-- and Y* is --C(O)-- or --C(R") 2 --! v where R" is hydrogen or C 1 -C 4 -alkyl and v is 1, 2 or 3, pyridin-2-on-1-yl, pyridin-4-on-1-yl, D-allose, D-altrose, D-glucose, D-mannose, D-gulose, D-idose, D-galactose, D-talose, D-ribose, D-arabinose, D-xylose, and D-lyxose wherein said heterocyclics are either unsubstituted or monosubstituted or disubstituted with substituents independently selected from hydroxy, halo, oxo (═O), amino, C 1 -C 10 -alkylamino, C 1 -C 10 -dialkylamino, C 1 -C 10 -alkoxy, alkoxy-C 1 -C 10 -alkoxy, alkoxy-C 1 -C 10 -alkyl, halo-C 1 -C 10 -alkyl, hydroxy, hydroxy-C 1 -C 10 -alkyl, C 3 -C 10 -cycloalkyl, aryl, aryl-C 1 -C 10 -alkyl, --COOH, --SO 3 H, --C(O)NH 2 and C 1 -C 10 -loweralkyl.
Claim 2
Independent Claim
1530 words
A method of immunomodulatory treatment comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compound having the formula: ##STR20## or a pharmaceutically acceptable salt, ester, amide or prodrug thereof wherein R 1 is hydrogen, a hydroxy protecting group, C 1 -C 10 -loweralkyl or phenyl-substituted C 1 -C 10 -loweralkyl; R 2 is hydrogen and R 3 is hydroxy or protected hydroxy or R 2 and R 3 taken together are oxo; R 4 is hydrogen or phenyl-substituted C 1 -C 10 loweralkyl and R 5 is hydroxy or protected hydroxy or R 5 is hydrogen or phenyl-substituted C 1 -C 10 -loweralkyl and R 4 is hydroxy or protected hydroxy or R 4 and R 5 taken together are oxo; R 6 is hydrogen or phenyl-substituted C 1 -C 10 -loweralkyl and R 7 is hydrogen, hydroxy or protected hydroxy or R 7 is hydrogen or phenyl-substituted C 1 -C 10 -loweralkyl and R 6 is hydroxy or protected hydroxy or R 6 and R 7 taken together are (1) oxo, (2) diazo, (3) ═CH 2 (4) --O--(CH 2 ) 2 --O--, (5) --S--(CH 2 ) 2 --S--, (6) --O--(CH 2 ) 3 --O--, (7) --S--(CH 2 ) 3 --S--, (8) ═N--OR 20 wherein R 20 is hydrogen, C 1 -C 10 -loweralkyl, C 2 -C 10 -alkenyl, C 3 -C 10 -cycloalkyl, C 3 -C 10 -cycloalkenyl, C 3 -C 10 -bicycloalkenyl, aryl, aryl-C 1 -C 10 -alkyl, heterocyclic or heterocyclic-C 1 -C 10 -alkyl, each of which is optionally substituted with C 1 -C 10 -loweralkyl, halogen, hydroxy, aryl or heterocyclic; or (9) ═N--N(R 21 )(R 22 ) wherein R 21 and R 22 are independently selected from hydrogen, C 1 -C 10 -loweralkyl, aryl, aryl-C 1 -C 10 -alkyl, heterocyclic and heterocyclic-C 1 -C 10 -alkyl; R 8 is hydrogen; R 9 is (1) --OS(O) 2 CF 3 , (2) --OS(O) 2 F, (3) --OS(O) 2 R 21a wherein R 21a is C 1 -C 10 -loweralkyl, aryl, aryl-C 1 -C 10 -alkyl, heterocyclic or heterocyclic-C 1 -C 10 -alkyl, (4) --OC(O)R 23 wherein R 23 is C 1 -C 10 -loweralkyl, C 3 -C 10 -cycloalkyl, C 3 -C 10 -cycloalkyl-C 1 -C 10 -alkyl, aryl, aryl-C 1 -C 10 -alkyl, heterocyclic, heterocyclic-C 1 -C 10 -alkyl, alkoxy, --O--C 3 -C 10 -cycloalkyl, --O-aryl, --O-heterocyclic, --O--(N-succinimidyl) or 5-tetrazolyl; (5) --OC(O)--N(R 24 )(R 25 ) wherein R 24 and R 25 are independently selected from (a) hydrogen, (b) C 1 -C 10 -loweralkyl, (c) C 2 -C 10 -alkenyl, (d) C 2 -C 10 -alkynyl, (e) C 3 -C 10 -cycloalkyl, (f) substituted C 1 -C 10 -loweralkyl, substituted C 2 -C 10 -alkenyl, substituted C 2 -C 10 -alkynyl or substituted C 3 -C 10 -cycloalkyl wherein the C 1 -C 10 -loweralkyl group, the C 2 -C 10 -alkenyl group, the C 2 -C 10 -alkynyl group or the C 3 -C 10 -cycloalkyl group is substituted by one or two substituents independently selected from (i) hydroxy, (ii) --COOH, (iii) --CN, (iv) --Q--C 1 -C 10 -loweralkyl, --Q-aryl, --Q-(aryl-C 1 -C 10 -alkyl), --Q-heterocyclic or --Q-(heterocyclicalkyl) wherein Q is --O--, --S--, --S(O)--, --S(O) 2 --, --C(O)--, --OC(O)--, --C(O)O--, --C(O)C(O)--O--, --O--C(O)C(O)--, --C(O)NH--, --NHC(O)--, --OC(O)NH--, --NHC(O)O--, --NH--C(O)--NH--, --S(O) 2 NH--, --NHS(O) 2 --, --N(R 27 )--, --C(NR 27 )NHNH-- and --NHNHC(NR 27 )-- wherein R 27 is hydrogen, C 1 -C 10 -loweralkyl, aryl or heterocyclic, (v) C 3 -C 10 -cycloalkyl, (vi) aryl, (vii) heterocyclic, (viii) --N(R 28 )(R 29 ) wherein R 28 and R 29 are independently selected from hydrogen, C 1 -C 10 -loweralkyl, hydroxy-C 1 -C 10 -alkyl, aryl and heterocyclic, (ix) guanidino, (x) --S(O) 2 R 11 wherein R 11 is C 1 -C 10 -loweralkyl, aryl or aryl-C 1 -C 10 -alkyl, (xi) --OS(O) 2 R 11 wherein R 11 is defined as above, (xii) --SO 3 H, (xiii) --S(O) 2 NH 2 , (xiv) --SR 28 wherein R 28 is defined as above, (xv) halogen, (xvi) oxo and (xvii) epoxy; (g) aryl, (h) heterocyclic, (i) --NHC(O)--O--(C 1 -C 10 -loweralkyl), (j) --NHC(O)-aryl, (k) --NHC(O)-heterocyclic and (l) C 1 -C 10 -loweralkyl substituted by --OC(O)--R f wherein R f is carboxy-C 3 -C 10 -alkyl or --N(R 24 )(R 25 ) taken together form a nitrogen-containing heterocyclic group, (6) --OR 25 wherein R 25 is as defined above, (7) a protected hydroxy group, (8) --OC(O)N(OR 24 )(R 25 ) wherein R 24 and R 25 are defined as above, (9) --O(CH 2 ) i C(O)OR 20 wherein i is one or two and R 20 is independently defined as above, (10) --O(CH(Si(CH 3 ) 3 ))-(CH 2 ) j C(O)OR 20 wherein j is zero or one and R 20 is independently defined as above, (11) --O(CH 2 ) i C(O)N(R 24 )(R 25 ) wherein i, R 24 and R 25 are defined as above, (12) --O(CH 2 ) i C(O)N(OR 24 )(R 25 ) wherein i, R 24 and R 25 are defined as above, (13) --O(CH 2 ) i C(O)N(R 24 )(N(R 24 )(R 25 )) wherein i, R 24 and R 25 are defined as above, (14) --O(CH 2 ) i NHC(O)N(R 24 )(R 25 ) wherein i, R 24 and R 25 are defined as above, (15) --O(CH 2 ) i NHC(O)N(OR 24 )(R 25 ) wherein i, R 24 and R 25 are defined as above, (16) --O(CH 2 ) i NHC(O)N(R 24 )(N(R 24 )(R 25 )) wherein i, R 24 and R 25 are defined as above, (17) --OS(O) 2 N(R 24 )(R 25 ) wherein R 24 and R 25 are defined as above, (18) --O(CH 2 ) i --NHC(O)R 24 wherein R 24 is defined as above, (19) --OCH(R 24 )--SH wherein R 24 is defined as above, (20) --OCH(R 24 )--S--C 1 -C 10 -loweralkyl wherein R 24 is defined as above, (21) --OCH(R 24 )--S-aryl wherein R 24 is defined as above and (22) --N 3 ; R 10a is hydrogen and R 10b is hydrogen, hydroxy, protected hydroxy, C 1 -C 10 -alkoxy, C 2 -C 10 -alkenyl, C 2 -C 10 -alkenyloxy, halogen or --SR 28 wherein R 28 is independently defined as above or R 10b is hydrogen and R 10a is hydrogen, hydroxy, protected hydroxy, C 1 -C 10 -alkoxy, C 2 -C 10 -alkenyl, C 2 -C 10 -alkenyloxy, halogen or --SR 28 wherein R 28 is independently defined as above or R 10a and R 10b are both C 1 -C 10 -alkoxy or --SR 28a wherein R 28a is C 1 -C 10 -loweralkyl, aryl or heterocyclic or R 10a and R 10b taken together are oxo; and X is hydrogen and Y is hydrogen, hydroxy or protected hydroxy or Y is hydrogen and X is hydroxy or protected hydroxy or X and Y taken together are oxo wherein at each occurrence the term "aryl" is independently selected from phenyl, naphthyl, fluorenyl, (1,2,3,4-)-tetrahydronaphthyl, indenyl and indanyl which is either unsubstituted or substituted with one, two, or three substituents independently selected from the group consisting of C 1 -C 10 -loweralkyl, halo, halo-C 1 -C 10 -loweralkyl, halo-C 1 -C 10 -alkoxy, C 2 -C 10 -alkenyloxy, C 1 -C 10 -alkoxy, alkoxy-C 1 -C 10 -alkoxy, C 1 -C 10 -alkoxycarbonyl, C 1 -C 10 -alkoxycarbonylalkenyl, (C 1 -C 10 -alkoxycarbonyl)thio-C 1 -C 10 -alkoxy, thio-C 1 -C 10 -alkoxy, amino, C 1 -C 10 -alkylamino, C 1 -C 10 -dialkylamino, aminocarbonyl, aminocarbonyl-C 1 -C 10 -alkoxy, alkanoylamino, aryl-C 1 -C 10 -alkoxy, aryloxy, mercapto, nitro, carboxaldehyde, carboxy, carboxy-C 2 -C 10 -alkenyl, carboxy-C 1 -C 10 -alkoxy, C 1 -C 10 -alkylsulfonylamino, cyano-C 1 -C 10 -alkoxy, (heterocyclic)-C 1 -C 10 -alkoxy, hydroxy, hydroxy-C 1 -C 10 -alkoxy, phenyl, phenyl-substituted C 2 -C 10 -alkenyl, phenyl-substituted C 2 -C 10 -alkynyl, heterocyclic, --S(O) 2 NH 2 , tetrazolyl-C 1 -C 10 -alkoxy, tetrafluorophenyl and pentafluorophenyl and at each occurrence the term "heterocyclic" is independently selected from indolyl, quinolyl, isoquinolyl, tetrahydroquinolyl, benzofuryl, dihydrobenzofuryl, benzothienyl, azetidinyl, oxetanyl, pyrrolyl, pyrrolinyl, pyrrolidinyl, pyrazolyl, pyrazolinyl, pyrazolidinyl, imidazolyl, imidazolinyl, imidazolidinyl, pyridyl, piperidinyl, homopiperidinyl, pyrazinyl, piperazinyl, pyrimidinyl, pyridazinyl, oxazolyl, oxazolidinyl, isoxazolyl, isoxazolidinyl, morpholinyl, thiomorpholinyl, thiazolyl, thiazolidinyl, isothiazolyl, isothiazolidinyl, indolyl, quinolinyl, isoquinolinyl, benzimidazolyl, benzothiazolyl, benzoxazolyl, furyl, thienyl, thiazolidinyl, isothiazolyl, triazolyl, tetrazolyl, isoxazolyl, oxadiazolyl, thiadiazolyl, pyrrolyl, pyrimidyl, benzothienyl, compounds of the formula ##STR21## where X* is --CH 2 -- or --O-- and Y* is --C(O)-- or --C(R") 2 --! v where R" is hydrogen or C 1 -C 4 -alkyl and v is 1, 2 or 3, pyridin-2-on-1-yl, pyridin-4-on-1-yl, D-allose, D-altrose, D-glucose, D-mannose, D-gulose, D-idose, D-galactose, D-talose, D-ribose, D-arabinose, D-xylose, and D-lyxose wherein said heterocyclics are either unsubstituted or monosubstituted or disubstituted with substituents independently selected from hydroxy, halo, oxo (═O), amino, C 1 -C 10 -alkylamino, C 1 -C 10 -dialkylamino, C 1 -C 10 -alkoxy, alkoxy-C 1 -C 10 -alkoxy, alkoxy-C 1 -C 10 -alkyl, halo-C 1 -C 10 -alkyl, hydroxy, hydroxy-C 1 -C 10 -alkyl, C 3 -C 10 -cycloalkyl, aryl, aryl-C 1 -C 10 -alkyl, --COOH, --SO 3 H, --C(O)NH 2 and C 1 -C 10 -loweralkyl.
Claim 3
Independent Claim
1160 words
A method of immunomodulatory treatment comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compound having the formula: ##STR22## or a pharmaceutically acceptable salt, ester, amide or prodrug thereof wherein R 1 is hydrogen, a hydroxy protecting group, C 1 -C 10 -loweralkyl or phenyl-substituted C 1 -C 10 -loweralkyl; R 2 is hydrogen and R 3 is hydroxy or protected hydroxy or R 2 and R 3 taken together are oxo; R 4 is hydrogen or phenyl-substituted C 1 -C 10 -loweralkyl and R 5 is hydroxy or protected hydroxy or R 5 is hydrogen or phenyl-substituted C 1 -C 10 -loweralkyl and R 4 is hydroxy or protected hydroxy or R 4 and R 5 taken together are oxo; R 6 is hydrogen or phenyl-substituted C 1 -C 10 -loweralkyl and R 7 is hydrogen, hydroxy or protected hydroxy or R 7 is hydrogen or phenyl-substituted C 1 -C 10 -loweralkyl and R 6 is hydroxy or protected hydroxy or R 6 and R 7 taken together are (1) oxo, (2) diazo, (3) ═CH 2 (4) --O--(CH 2 ) 2 --O--, (5) --S--(CH 2 ) 2 --S--, (6) --O--(CH 2 ) 3 --O--, (7) --S--(CH 2 ) 3 --S--, (8) ═N--OR 20 wherein R 20 is hydrogen, C 1 -C 10 -loweralkyl, C 2 -C 10 -alkenyl, C 3 -C 10 -cycloalkyl, C 3 -C 10 -cycloalkenyl, C 3 -C 10 -bicycloalkenyl, aryl, aryl-C 1 -C 10 -alkyl, heterocyclic or heterocyclic-C 1 -C 10 -alkyl, each of which is optionally substituted with C 1 -C 10 -loweralkyl, halogen, hydroxy, aryl or heterocyclic; or (9) ═N--N(R 21 )(R 22 ) wherein R 21 and R 22 are independently selected from hydrogen, C 1 -C 10 -loweralkyl, aryl, aryl-C 1 -C 10 -alkyl, heterocyclic and heterocyclic-C 1 -C 10 -alkyl; R 8 is hydrogen; R 9 is (1) --SR 24 wherein R 24 is (a) hydrogen, (b) C 1 -C 10 -loweralkyl, (c) C 2 -C 10 -alkenyl, (d) C 2 -C 10 -alkynyl, (e) C 3 -C 10 -cycloalkyl, (f) substituted C 1 -C 10 -loweralkyl, substituted C 2 -C 10 -alkenyl, substituted C 2 -C 10 -alkynyl or substituted C 3 -C 10 -cycloalkyl wherein the C 1 -C 10 -loweralkyl group, the C 2 -C 10 -alkenyl group, the C 2 -C 10 -alkynyl group or the C 3 -C 10 -cycloalkyl group is substituted by one or two substituents independently selected from (i) hydroxy, (ii) --COOH, (iii) --CN, (iv) --Q--C 1 -C 10 -loweralkyl, --Q-aryl, --Q-(aryl-C 1 -C 10 -alkyl), --Q-heterocyclic or --Q-(heterocyclic-C 1 -C 10 -alkyl) wherein Q, is --O--, --S--, --S(O)--, --S(O) 2 --, --C(O)--, --OC(O)--, --C(O)O--, --C(O)C(O)--O--, --O--C(O)C(O)--, --C(O)NH--, --NHC(O)--, --OC(O)NH--, --NHC(O)O--, --NH--C(O)--NH--, --S(O) 2 NH--, --NHS(O) 2 --, --N(R 27 )--, --C(NR 27 )NHNH-- and --NHNHC(NR 27 )-- wherein R 27 is hydrogen, C 1 -C 10 -loweralkyl, aryl or heterocyclic, (v) C 3 -C 10 -cycloalkyl, (vi) aryl, (vii) heterocyclic, (viii) --N(R 28 )(R 29 ) wherein R 28 and R 29 are independently selected from hydrogen, C 1 -C 10 -loweralkyl, hydroxy-C 1 -C 10 -alkyl, aryl and heterocyclic, (ix) guanidino, (x) --S(O) 2 R 11 wherein R 11 is C 1 -C 10 -loweralkyl, aryl or aryl-C 1 -C 10 -alkyl, (xi) --OS(O) 2 R 11 wherein R 11 is defined as above, (xii) --SO 3 H, (xiii) --S(O) 2 NH 2 , (xiv) --SR 28 wherein R 28 is defined as above, (xv) halogen, (xvi) oxo and (xvii) epoxy; (g) aryl, (h) heterocyclic, (i) --C(O)--O--(C 1 -C 10 -loweralkyl), (j) --C(O)-aryl, (k) --C(O)-heterocyclic or (l) C 1 -C 10 -loweralkyl substituted by --OC(O)--R f wherein R f is C 3 -C 10 -carboxyalkyl, (2) --SC(═NH)--NH 2 , (3) --SC(═N--NH 2 )--NH 2 , (4) --Se-phenyl or (5) --Se(O)-phenyl; R 10a is hydrogen and R 10b is hydrogen, hydroxy, protected hydroxy, C 1 -C 10 -alkoxy, C 2 -C 10 -alkenyl, C 2 -C 10 -alkenyloxy, halogen or --SR 28 wherein R 28 is independently defined as above or R 10b is hydrogen and R 10a is hydrogen, hydroxy, protected hydroxy, C 1 -C 10 -alkoxy, C 2 -C 10 -alkenyl, C 2 -C 10 -alkenyloxy, halogen or --SR 28 wherein R 28 is independently defined as above or R 10a and R 10b are both C 1 -C 10 -alkoxy or --SR 28a wherein R 28a is C 1 -C 10 -loweralkyl, aryl or heterocyclic or R 10a and R 10b taken together are oxo; and X is hydrogen and Y is hydrogen, hydroxy or protected hydroxy or Y is hydrogen and X is hydroxy or protected hydroxy or X and Y taken together are oxo wherein at each occurrence the term "aryl" is independently selected from phenyl, naphthyl, fluorenyl, (1,2,3,4-)-tetrahydronaphthyl, indenyl and indanyl which is either unsubstituted or substituted with one, two, or three substituents independently selected from the group consisting of C 1 -C 10 -loweralkyl, halo, halo-C 1 -C 10 -loweralkyl, halo-C 1 -C 10 -alkoxy, C 2 -C 10 -alkenyloxy, C 1 -C 10 -alkoxy, alkoxy-C 1 -C 10 -alkoxy, C 1 -C 10 -alkoxycarbonyl, C 1 -C 10 -alkoxycarbonylalkenyl, (C 1 -C 10 -alkoxycarbonyl)thio-C 1 -C 10 -alkoxy, thio-C 1 -C 10 -alkoxy, amino, C 1 -C 10 -alkylamino, C 1 -C 10 -dialkylamino, aminocarbonyl, aminocarbonyl-C 1 -C 10 -alkoxy, alkanoylamino, aryl-C 1 -C 10 -alkoxy, aryloxy, mercapto, nitro, carboxaldehyde, carboxy, carboxy-C 2 -C 10 -alkenyl, carboxy-C 1 -C 10 -alkoxy, C 1 -C 10 -alkylsulfonylamino, cyano-C 1 -C 10 -alkoxy, (heterocyclic)-C 1 -C 10 -alkoxy, hydroxy, hydroxy-C 1 -C 10 -alkoxy, phenyl, phenyl-substituted C 2 -C 10 -alkenyl, phenyl-substituted C 2 -C 10 -alkynyl, heterocyclic, --S(O) 2 NH 2 , tetrazolyl-C 1 -C 10 -alkoxy, tetrafluorophenyl and pentafluorophenyl and at each occurrence the term "heterocyclic" is independently selected from indolyl, quinolyl, isoquinolyl, tetrahydroquinolyl, benzofuryl, dihydrobenzofuryl, benzothienyl, azetidinyl, oxetanyl, pyrrolyl, pyrrolinyl, pyrrolidinyl, pyrazolyl, pyrazolinyl, pyrazolidinyl, imidazolyl, imidazolinyl, imidazolidinyl, pyridyl, piperidinyl, homopiperidinyl, pyrazinyl, piperazinyl, pyrimidinyl, pyridazinyl, oxazolyl, oxazolidinyl, isoxazolyl, isoxazolidinyl, morpholinyl, thiomorpholinyl, thiazolyl, thiazolidinyl, isothiazolyl, isothiazolidinyl, indolyl, quinolinyl, isoquinolinyl, benzimidazolyl, benzothiazolyl, benzoxazolyl, furyl, thienyl, thiazolidinyl, isothiazolyl, triazolyl, tetrazolyl, isoxazolyl, oxadiazolyl, thiadiazolyl, pyrrolyl, pyrimidyl, benzothienyl, compounds of the formula ##STR23## where X* is --CH 2 -- or --O-- and Y* is --C(O)-- or --C(R") 2 --! v where R" is hydrogen or C 1 -C 4 -alkyl and v is 1, 2 or 3, pyridin-2-on-1-yl, pyridin-4-on-1-yl, D-allose, D-altrose, D-glucose, D-mannose, D-gulose, D-idose, D-galactose, D-talose, D-ribose, D-arabinose, D-xylose, and D-lyxose wherein said heterocyclics are either unsubstituted or monosubstituted or disubstituted with substituents independently selected from hydroxy, halo, oxo (═O), amino, C 1 -C 10 -alkylamino, C 1 -C 10 -dialkylamino, C 1 -C 10 -alkoxy, alkoxy-C 1 -C 10 -alkoxy, alkoxy-C 1 -C 10 -alkyl, halo-C 1 -C 10 -alkyl, hydroxy, hydroxy-C 1 -C 10 -alkyl, C 3 -C 10 -cycloalkyl, aryl, aryl-C 1 -C 10 -alkyl, --COOH, --SO 3 H, --C(O)NH 2 and C 1 -C 10 -loweralkyl.
Claim 4
Independent Claim
1160 words
A method of immunomodulatory treatment comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compound having the formula: ##STR22## or a pharmaceutically acceptable salt, ester, amide or prodrug thereof wherein R 1 is hydrogen, a hydroxy protecting group, C 1 -C 10 -loweralkyl or phenyl-substituted C 1 -C 10 -loweralkyl; R 2 is hydrogen and R 3 is hydroxy or protected hydroxy or R 2 and R 3 taken together are oxo; R 4 is hydrogen or phenyl-substituted C 1 -C 10 -loweralkyl and R 5 is hydroxy or protected hydroxy or R 5 is hydrogen or phenyl-substituted C 1 -C 10 -loweralkyl and R 4 is hydroxy or protected hydroxy or R 4 and R 5 taken together are oxo; R 6 is hydrogen or phenyl-substituted C 1 -C 10 -loweralkyl and R 7 is hydrogen, hydroxy or protected hydroxy or R 7 is hydrogen or phenyl-substituted C 1 -C 10 -loweralkyl and R 6 is hydroxy or protected hydroxy or R 6 and R 7 taken together are (1) oxo, (2) diazo, (3) ═CH 2 (4) --O--(CH 2 ) 2 --O--, (5) --S--(CH 2 ) 2 --S--, (6) --O--(CH 2 ) 3 --O--, (7) --S--(CH 2 ) 3 --S--, (8) ═N--OR 20 wherein R 20 is hydrogen, C 1 -C 10 -loweralkyl, C 2 -C 10 -alkenyl, C 3 -C 10 -cycloalkyl, C 3 -C 10 -cycloalkenyl, C 3 -C 10 -bicycloalkenyl, aryl, aryl-C 1 -C 10 -alkyl, heterocyclic or heterocyclic-C 1 -C 10 -alkyl, each of which is optionally substituted with C 1 -C 10 -loweralkyl, halogen, hydroxy, aryl or heterocyclic; or (9) ═N--N(R 21 )(R 22 ) wherein R 21 and R 22 are independently selected from hydrogen, C 1 -C 10 -loweralkyl, aryl, aryl-C 1 -C 10 -alkyl, heterocyclic and heterocyclic-C 1 -C 10 -alkyl; R 8 is hydrogen; R 9 is (1) --SR 24 wherein R 24 is (a) hydrogen, (b) C 1 -C 10 -loweralkyl, (c) C 2 -C 10 -alkenyl, (d) C 2 -C 10 -alkynyl, (e) C 3 -C 10 -cycloalkyl, (f) substituted C 1 -C 10 -loweralkyl, substituted C 2 -C 10 -alkenyl, substituted C 2 -C 10 -alkynyl or substituted C 3 -C 10 -cycloalkyl wherein the C 1 -C 10 -loweralkyl group, the C 2 -C 10 -alkenyl group, the C 2 -C 10 -alkynyl group or the C 3 -C 10 -cycloalkyl group is substituted by one or two substituents independently selected from (i) hydroxy, (ii) --COOH, (iii) --CN, (iv) --Q--C 1 -C 10 -loweralkyl, --Q-aryl, --Q-(aryl-C 1 -C 10 -alkyl), --Q-heterocyclic or --Q-(heterocyclic-C 1 -C 10 -alkyl) wherein Q, is --O--, --S--, --S(O)--, --S(O) 2 --, --C(O)--, --OC(O)--, --C(O)O--, --C(O)C(O)--O--, --O--C(O)C(O)--, --C(O)NH--, --NHC(O)--, --OC(O)NH--, --NHC(O)O--, --NH--C(O)--NH--, --S(O) 2 NH--, --NHS(O) 2 --, --N(R 27 )--, --C(NR 27 )NHNH-- and --NHNHC(NR 27 )-- wherein R 27 is hydrogen, C 1 -C 10 -loweralkyl, aryl or heterocyclic, (v) C 3 -C 10 -cycloalkyl, (vi) aryl, (vii) heterocyclic, (viii) --N(R 28 )(R 29 ) wherein R 28 and R 29 are independently selected from hydrogen, C 1 -C 10 -loweralkyl, hydroxy-C 1 -C 10 -alkyl, aryl and heterocyclic, (ix) guanidino, (x) --S(O) 2 R 11 wherein R 11 is C 1 -C 10 -loweralkyl, aryl or aryl-C 1 -C 10 -alkyl, (xi) --OS(O) 2 R 11 wherein R 11 is defined as above, (xii) --SO 3 H, (xiii) --S(O) 2 NH 2 , (xiv) --SR 28 wherein R 28 is defined as above, (xv) halogen, (xvi) oxo and (xvii) epoxy; (g) aryl, (h) heterocyclic, (i) --C(O)--O--(C 1 -C 10 -loweralkyl), (j) --C(O)-aryl, (k) --C(O)-heterocyclic or (l) C 1 -C 10 -loweralkyl substituted by --OC(O)--R f wherein R f is C 3 -C 10 -carboxyalkyl, (2) --SC(═NH)--NH 2 , (3) --SC(═N--NH 2 )--NH 2 , (4) --Se-phenyl or (5) --Se(O)-phenyl; R 10a is hydrogen and R 10b is hydrogen, hydroxy, protected hydroxy, C 1 -C 10 -alkoxy, C 2 -C 10 -alkenyl, C 2 -C 10 -alkenyloxy, halogen or --SR 28 wherein R 28 is independently defined as above or R 10b is hydrogen and R 10a is hydrogen, hydroxy, protected hydroxy, C 1 -C 10 -alkoxy, C 2 -C 10 -alkenyl, C 2 -C 10 -alkenyloxy, halogen or --SR 28 wherein R 28 is independently defined as above or R 10a and R 10b are both C 1 -C 10 -alkoxy or --SR 28a wherein R 28a is C 1 -C 10 -loweralkyl, aryl or heterocyclic or R 10a and R 10b taken together are oxo; and X is hydrogen and Y is hydrogen, hydroxy or protected hydroxy or Y is hydrogen and X is hydroxy or protected hydroxy or X and Y taken together are oxo wherein at each occurrence the term "aryl" is independently selected from phenyl, naphthyl, fluorenyl, (1,2,3,4-)-tetrahydronaphthyl, indenyl and indanyl which is either unsubstituted or substituted with one, two, or three substituents independently selected from the group consisting of C 1 -C 10 -loweralkyl, halo, halo-C 1 -C 10 -loweralkyl, halo-C 1 -C 10 -alkoxy, C 2 -C 10 -alkenyloxy, C 1 -C 10 -alkoxy, alkoxy-C 1 -C 10 -alkoxy, C 1 -C 10 -alkoxycarbonyl, C 1 -C 10 -alkoxycarbonylalkenyl, (C 1 -C 10 -alkoxycarbonyl)thio-C 1 -C 10 -alkoxy, thio-C 1 -C 10 -alkoxy, amino, C 1 -C 10 -alkylamino, C 1 -C 10 -dialkylamino, aminocarbonyl, aminocarbonyl-C 1 -C 10 -alkoxy, alkanoylamino, aryl-C 1 -C 10 -alkoxy, aryloxy, mercapto, nitro, carboxaldehyde, carboxy, carboxy-C 2 -C 10 -alkenyl, carboxy-C 1 -C 10 -alkoxy, C 1 -C 10 -alkylsulfonylamino, cyano-C 1 -C 10 -alkoxy, (heterocyclic)-C 1 -C 10 -alkoxy, hydroxy, hydroxy-C 1 -C 10 -alkoxy, phenyl, phenyl-substituted C 2 -C 10 -alkenyl, phenyl-substituted C 2 -C 10 -alkynyl, heterocyclic, --S(O) 2 NH 2 , tetrazolyl-C 1 -C 10 -alkoxy, tetrafluorophenyl and pentafluorophenyl and at each occurrence the term "heterocyclic" is independently selected from indolyl, quinolyl, isoquinolyl, tetrahydroquinolyl, benzofuryl, dihydrobenzofuryl, benzothienyl, azetidinyl, oxetanyl, pyrrolyl, pyrrolinyl, pyrrolidinyl, pyrazolyl, pyrazolinyl, pyrazolidinyl, imidazolyl, imidazolinyl, imidazolidinyl, pyridyl, piperidinyl, homopiperidinyl, pyrazinyl, piperazinyl, pyrimidinyl, pyridazinyl, oxazolyl, oxazolidinyl, isoxazolyl, isoxazolidinyl, morpholinyl, thiomorpholinyl, thiazolyl, thiazolidinyl, isothiazolyl, isothiazolidinyl, indolyl, quinolinyl, isoquinolinyl, benzimidazolyl, benzothiazolyl, benzoxazolyl, furyl, thienyl, thiazolidinyl, isothiazolyl, triazolyl, tetrazolyl, isoxazolyl, oxadiazolyl, thiadiazolyl, pyrrolyl, pyrimidyl, benzothienyl, compounds of the formula ##STR23## where X* is --CH 2 -- or --O-- and Y* is --C(O)-- or --C(R") 2 --! v where R" is hydrogen or C 1 -C 4 -alkyl and v is 1, 2 or 3, pyridin-2-on-1-yl, pyridin-4-on-1-yl, D-allose, D-altrose, D-glucose, D-mannose, D-gulose, D-idose, D-galactose, D-talose, D-ribose, D-arabinose, D-xylose, and D-lyxose wherein said heterocyclics are either unsubstituted or monosubstituted or disubstituted with substituents independently selected from hydroxy, halo, oxo (═O), amino, C 1 -C 10 -alkylamino, C 1 -C 10 -dialkylamino, C 1 -C 10 -alkoxy, alkoxy-C 1 -C 10 -alkoxy, alkoxy-C 1 -C 10 -alkyl, halo-C 1 -C 10 -alkyl, hydroxy, hydroxy-C 1 -C 10 -alkyl, C 3 -C 10 -cycloalkyl, aryl, aryl-C 1 -C 10 -alkyl, --COOH, --SO 3 H, --C(O)NH 2 and C 1 -C 10 -loweralkyl.
Claim 5
Independent Claim
1423 words
A method of immunomodulatory treatment comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compound having the formula: ##STR24## or a pharmaceutically acceptable salt, ester, amide or prodrug thereof wherein R 1 is hydrogen, a hydroxy protecting group, C 1 -C 10 -loweralkyl or phenyl-substituted C 1 -C 10 -loweralkyl; R 2 is hydrogen and R 3 is hydroxy or protected hydroxy or R 2 and R 3 taken together are oxo; R 4 is hydrogen or phenyl-substituted C 1 -C 10 -loweralkyl and R 5 is hydroxy or protected hydroxy or R 5 is hydrogen or phenyl-substituted C 1 -C 10 -loweralkyl and R 4 is hydroxy or protected hydroxy or R 4 and R 5 taken together are oxo; R 6 is hydrogen or phenyl-substituted C 1 -C 10 -loweralkyl and R 7 is hydrogen, hydroxy or protected hydroxy or R 7 is hydrogen or phenyl-substituted C 1 -C 10 -loweralkyl and R 6 is hydroxy or protected hydroxy or R 6 and R 7 taken together are (1) oxo, (2) diazo, (3) ═CH 2 (4) --O--(CH 2 ) 2 --O--, (5) --S--(CH 2 ) 2 --S--, (6) --O--(CH 2 ) 3 --O--, (7) --S--(CH 2 ) 3 --S--, (8) ═N--OR 20 wherein R 20 is hydrogen, C 1 -C 10 -loweralkyl, C 2 -C 10 -alkenyl, C 3 -C 10 -cycloalkyl, C 3 -C 10 -cycloalkenyl, C 3 -C 10 -bicycloalkenyl, aryl, aryl-C 1 -C 10 -alkyl, heterocyclic or heterocyclic-C 1 -C 10 -alkyl, each of which is optionally substituted with C 1 -C 10 -loweralkyl, halogen, hydroxy, aryl or heterocyclic; or (9) ═N--N(R 21 )(R 22 ) wherein R 21 and R 22 are independently selected from hydrogen, C 1 -C 10 -loweralkyl, aryl, aryl-C 1 -C 10 -alkyl, heterocyclic and heterocyclic-C 1 -C 10 -alkyl; R 8 is hydrogen; R 9 is (1) --N(R 24 )(R 25 ) wherein R 24 and R 25 are independently selected from (a) hydrogen, (b) C 1 -C 10 -loweralkyl, (c) C 2 -C 10 -alkenyl, (d) C 2 -C 10 -alkynyl, (e) C 3 -C 10 -cycloalkyl, (f) substituted C 1 -C 10 -loweralkyl, substituted C 2 -C 10 -alkenyl, substituted C 2 -C 10 -alkynyl or substituted C 3 -C 10 -cycloalkyl wherein the C 1 -C 10 -loweralkyl group, the C 2 -C 10 -alkenyl group, the C 2 -C 10 -alkynyl group or the C 3 -C 10 -cycloalkyl group is substituted by one or two substituents independently selected from (i) hydroxy, (ii) --COOH, (iii) --CN, (iv) --Q--(C 1 -C 10 -loweralkyl), --Q-aryl, --Q-(aryl-C 1 -C 10 -alkyl), --Q-heterocyclic or --Q-(heterocyclic-C 1 -C 10 -alkyl) wherein Q is --O--, --S--, --S(O)--, --S(O) 2 --, --C(O)--, --OC(O)--, --C(O)O--, --C(O)C(O)--O--, --O--C(O)C(O)--, --C(O)NH--, --NHC(O)--, --OC(O)NH--, --NHC(O)O--, --NH--C(O)--NH--, --S(O) 2 NH--, --NHS(O) 2 --, --N(R 27 )--, --C(NR 27 )NHNH-- and --NHNHC(NR 27 )-- wherein R 27 is hydrogen, C 1 -C 10 -loweralkyl, aryl or heterocyclic, (v) C 3 -C 10 -cycloalkyl, (vi) aryl, (vii) heterocyclic, (viii) --N(R 28 )(R 29 ) wherein R 28 and R 29 are independently selected from hydrogen, C 1 -C 10 -loweralkyl, hydroxy-C 1 -C 10 -alkyl, aryl and heterocyclic, (ix) guanidino, (x) --S(O) 2 R 11 wherein R 11 is C 1 -C 10 -loweralkyl, aryl or aryl-C 1 -C 10 -alkyl, (xi) --OS(O) 2 R 11 wherein R 11 is defined as above, (xii) --SO 3 H, (xiii) --S(O) 2 NH 2 , (xiv) --SR 28 wherein R 28 is defined as above, (xv) halogen, (xvi) oxo and (xvii) epoxy; (g) aryl, (h) heterocyclic, (i) --NHC(O)--O--(C 1 -C 10 -loweralkyl), (j) --NHC(O)-aryl, (k) --NHC(O)-heterocyclic and (l) C 1 -C 10 -loweralkyl substituted by --OC(O)--R f wherein R f is C 3 -C 10 -carboxyalkyl, (2) --N═C═O, (3) --NHC(O)--R* or (4) --NHS(O) 2 --R* wherein R* is (a) C 1 -C 10 -loweralkyl, (b) C 3 -C 10 -cycloalkyl, (c) aryl, (d) heterocyclic, (e) C 1 -C 10 -loweralkyl substituted by one or two substituents independently selected from (i) hydroxy, (ii) --COOH, (iii) --CN, (iv) --Q--(C 1 -C 10 -loweralkyl), --Q-aryl, --Q-(aryl-C 1 -C 10 -alkyl), --Q-heterocyclic or --Q-(heterocyclic-C 1 -C 10 -alkyl) wherein Q is --O--, --S--, --S(O)--, --S(O) 2 --, --C(O)--, --OC(O)--, --C(O)O--, --C(O)C(O)--O--, --O--C(O)C(O)--, --C(O)NH--, --NHC(O)--, --OC(O)NH--, --NHC(O)O--, --NH--C(O)--NH--, --S(O) 2 NH--, --NHS(O) 2 --, --N(R 27 )--, --C(NR 27 )NHNH-- and --NHNHC(NR 27 )-- wherein R 27 is hydrogen, C 1 -C 10 -loweralkyl, aryl or heterocyclic, (v) C 3 -C 10 -cycloalkyl, (vi) aryl, (vii) heterocyclic, (viii) --N(R 28 )(R 29 ) wherein R 28 and R 29 are independently selected from hydrogen, C 1 -C 10 -loweralkyl, hydroxy-C 1 -C 10 -alkyl, aryl and heterocyclic, (ix) guanidino, (x) --S(O) 2 R 11 wherein R 11 is C 1 -C 10 -loweralkyl, aryl or aryl-C 1 -C 10 -alkyl, (xi) --OS(O) 2 R 11 wherein R 11 is defined as above, (xii) --SO 3 H, (xiii) --S(O) 2 NH 2 , (xiv) --SR 28 wherein R 28 is defined as above, (xv) halogen, (xvi) oxo and (xvii) epoxy; (f) --N(R a )(R b ) wherein R a and R b are independently selected from hydrogen, C 1 -C 10 -loweralkyl and --N(R c )(R d ) wherein R c and R d are independently selected from hydrogen and C 1 -C 10 -loweralkyl or (g) --OR* wherein R* is defined as above; R 10a is hydrogen and R 10b is hydrogen, hydroxy, protected hydroxy, C 1 -C 10 -alkoxy, C 2 -C 10 -alkenyl, C 2 -C 10 -alkenyloxy, halogen or --SR 28 wherein R 28 is independently defined as above or R 10b is hydrogen and R 10a is hydrogen, hydroxy, protected hydroxy, C 1 -C 10 -alkoxy, C 2 -C 10 -alkenyl, C 2 -C 10 -alkenyloxy, halogen or --SR 28 wherein R 28 is independently defined as above or R 10a and R 10b are both alkoxy or --SR 28a wherein R 28a is C 1 -C 10 -loweralkyl, aryl or heterocyclic or R 10a and R 10b taken together are oxo; and X is hydrogen and Y is hydrogen, hydroxy or protected hydroxy or Y is hydrogen and X is hydroxy or protected hydroxy or X and Y taken together are oxo wherein at each occurrence the term "aryl" is independently selected from phenyl, naphthyl, fluorenyl, (1,2,3,4-)-tetrahydronaphthyl, indenyl and indanyl which is either unsubstituted or substituted with one, two, or three substituents independently selected from the group consisting of C 1 -C 10 -loweralkyl, halo, halo-C 1 -C 10 -loweralkyl, halo-C 1 -C 10 -alkoxy, C 2 -C 10 -alkenyloxy, C 1 -C 10 -alkoxy, alkoxy-C 1 -C 10 -alkoxy, C 1 -C 10 -alkoxycarbonyl, C 1 -C 10 -alkoxycarbonylalkenyl, (C 1 -C 10 -alkoxycarbonyl )thio-C 1 -C 10 -alkoxy, thio-C 1 -C 10 -alkoxy, amino, C 1 -C 10 -alkylamino, C 1 -C 10 -dialkylamino, aminocarbonyl, aminocarbonyl-C 1 -C 10 -alkoxy, alkanoylamino, aryl-C 1 -C 10 -alkoxy, aryloxy, mercapto, nitro, carboxaldehyde, carboxy, carboxy-C 2 -C 10 -alkenyl, carboxy-C 1 -C 10 -alkoxy, C 1 -C 10 -alkylsulfonylamino, cyano-C 1 -C 10 -alkoxy, (heterocyclic)-C 1 -C 10 -alkoxy, hydroxy, hydroxy-C 1 -C 10 -alkoxy, phenyl, phenyl-substituted C 2 -C 10 -alkenyl, phenyl-substituted C 2 -C 10 -alkynyl, heterocyclic, --S(O) 2 NH 2 , tetrazolyl-C 1 -C 10 -alkoxy, tetrafluorophenyl and pentafluorophenyl and at each occurrence the term "heterocyclic" is independently selected from indolyl, quinolyl, isoquinolyl, tetrahydroquinolyl, benzofuryl, dihydrobenzofuryl, benzothienyl, azetidinyl, oxetanyl, pyrrolyl, pyrrolinyl, pyrrolidinyl, pyrazolyl, pyrazolinyl, pyrazolidinyl, imidazolyl, imidazolinyl, imidazolidinyl, pyridyl, piperidinyl, homopiperidinyl, pyrazinyl, piperazinyl, pyrimidinyl, pyridazinyl, oxazolyl, oxazolidinyl, isoxazolyl, isoxazolidinyl, morpholinyl, thiomorpholinyl, thiazolyl, thiazolidinyl, isothiazolyl, isothiazolidinyl, indolyl, quinolinyl, isoquinolinyl, benzimidazolyl, benzothiazolyl, benzoxazolyl, furyl, thienyl, thiazolidinyl, isothiazolyl, triazolyl, tetrazolyl, isoxazolyl, oxadiazolyl, thiadiazolyl, pyrrolyl, pyrimidyl, benzothienyl, compounds of the formula ##STR25## where X* is --CH 2 -- or --O-- and Y* is --C(O)-- or --C(R") 2 --! v where R" is hydrogen or C 1 -C 4 -alkyl and v is 1, 2 or 3, pyridin-2-on-1-yl, pyridin-4-on-1-yl, D-allose, D-altrose, D-glucose, D-mannose, D-gulose, D-idose, D-galactose, D-talose, D-ribose, D-arabinose, D-xylose, and D-lyxose wherein said heterocyclics are either unsubstituted or monosubstituted or disubstituted with substituents independently selected from hydroxy, halo, oxo (═O), amino, C 1 -C 10 -alkylamino, C 1 -C 10 -dialkylamino, C 1 -C 10 -alkoxy, alkoxy-C 1 -C 10 -alkoxy, alkoxy-C 1 -C 10 -alkyl, halo-C 1 -C 10 -alkyl, hydroxy, hydroxy-C 1 -C 10 -alkyl, C 3 -C 10 -cycloalkyl, aryl, aryl-C 1 -C 10 -alkyl, --COOH, --SO 3 H, --C(O)NH 2 and C 1 -C 10 -loweralkyl.
Claim 6
Independent Claim
1423 words
A method of immunomodulatory treatment comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compound having the formula: ##STR24## or a pharmaceutically acceptable salt, ester, amide or prodrug thereof wherein R 1 is hydrogen, a hydroxy protecting group, C 1 -C 10 -loweralkyl or phenyl-substituted C 1 -C 10 -loweralkyl; R 2 is hydrogen and R 3 is hydroxy or protected hydroxy or R 2 and R 3 taken together are oxo; R 4 is hydrogen or phenyl-substituted C 1 -C 10 -loweralkyl and R 5 is hydroxy or protected hydroxy or R 5 is hydrogen or phenyl-substituted C 1 -C 10 -loweralkyl and R 4 is hydroxy or protected hydroxy or R 4 and R 5 taken together are oxo; R 6 is hydrogen or phenyl-substituted C 1 -C 10 -loweralkyl and R 7 is hydrogen, hydroxy or protected hydroxy or R 7 is hydrogen or phenyl-substituted C 1 -C 10 -loweralkyl and R 6 is hydroxy or protected hydroxy or R 6 and R 7 taken together are (1) oxo, (2) diazo, (3) ═CH 2 (4) --O--(CH 2 ) 2 --O--, (5) --S--(CH 2 ) 2 --S--, (6) --O--(CH 2 ) 3 --O--, (7) --S--(CH 2 ) 3 --S--, (8) ═N--OR 20 wherein R 20 is hydrogen, C 1 -C 10 -loweralkyl, C 2 -C 10 -alkenyl, C 3 -C 10 -cycloalkyl, C 3 -C 10 -cycloalkenyl, C 3 -C 10 -bicycloalkenyl, aryl, aryl-C 1 -C 10 -alkyl, heterocyclic or heterocyclic-C 1 -C 10 -alkyl, each of which is optionally substituted with C 1 -C 10 -loweralkyl, halogen, hydroxy, aryl or heterocyclic; or (9) ═N--N(R 21 )(R 22 ) wherein R 21 and R 22 are independently selected from hydrogen, C 1 -C 10 -loweralkyl, aryl, aryl-C 1 -C 10 -alkyl, heterocyclic and heterocyclic-C 1 -C 10 -alkyl; R 8 is hydrogen; R 9 is (1) --N(R 24 )(R 25 ) wherein R 24 and R 25 are independently selected from (a) hydrogen, (b) C 1 -C 10 -loweralkyl, (c) C 2 -C 10 -alkenyl, (d) C 2 -C 10 -alkynyl, (e) C 3 -C 10 -cycloalkyl, (f) substituted C 1 -C 10 -loweralkyl, substituted C 2 -C 10 -alkenyl, substituted C 2 -C 10 -alkynyl or substituted C 3 -C 10 -cycloalkyl wherein the C 1 -C 10 -loweralkyl group, the C 2 -C 10 -alkenyl group, the C 2 -C 10 -alkynyl group or the C 3 -C 10 -cycloalkyl group is substituted by one or two substituents independently selected from (i) hydroxy, (ii) --COOH, (iii) --CN, (iv) --Q--(C 1 -C 10 -loweralkyl), --Q-aryl, --Q-(aryl-C 1 -C 10 -alkyl), --Q-heterocyclic or --Q-(heterocyclic-C 1 -C 10 -alkyl) wherein Q is --O--, --S--, --S(O)--, --S(O) 2 --, --C(O)--, --OC(O)--, --C(O)O--, --C(O)C(O)--O--, --O--C(O)C(O)--, --C(O)NH--, --NHC(O)--, --OC(O)NH--, --NHC(O)O--, --NH--C(O)--NH--, --S(O) 2 NH--, --NHS(O) 2 --, --N(R 27 )--, --C(NR 27 )NHNH-- and --NHNHC(NR 27 )-- wherein R 27 is hydrogen, C 1 -C 10 -loweralkyl, aryl or heterocyclic, (v) C 3 -C 10 -cycloalkyl, (vi) aryl, (vii) heterocyclic, (viii) --N(R 28 )(R 29 ) wherein R 28 and R 29 are independently selected from hydrogen, C 1 -C 10 -loweralkyl, hydroxy-C 1 -C 10 -alkyl, aryl and heterocyclic, (ix) guanidino, (x) --S(O) 2 R 11 wherein R 11 is C 1 -C 10 -loweralkyl, aryl or aryl-C 1 -C 10 -alkyl, (xi) --OS(O) 2 R 11 wherein R 11 is defined as above, (xii) --SO 3 H, (xiii) --S(O) 2 NH 2 , (xiv) --SR 28 wherein R 28 is defined as above, (xv) halogen, (xvi) oxo and (xvii) epoxy; (g) aryl, (h) heterocyclic, (i) --NHC(O)--O--(C 1 -C 10 -loweralkyl), (j) --NHC(O)-aryl, (k) --NHC(O)-heterocyclic and (l) C 1 -C 10 -loweralkyl substituted by --OC(O)--R f wherein R f is C 3 -C 10 -carboxyalkyl, (2) --N═C═O, (3) --NHC(O)--R* or (4) --NHS(O) 2 --R* wherein R* is (a) C 1 -C 10 -loweralkyl, (b) C 3 -C 10 -cycloalkyl, (c) aryl, (d) heterocyclic, (e) C 1 -C 10 -loweralkyl substituted by one or two substituents independently selected from (i) hydroxy, (ii) --COOH, (iii) --CN, (iv) --Q--(C 1 -C 10 -loweralkyl), --Q-aryl, --Q-(aryl-C 1 -C 10 -alkyl), --Q-heterocyclic or --Q-(heterocyclic-C 1 -C 10 -alkyl) wherein Q is --O--, --S--, --S(O)--, --S(O) 2 --, --C(O)--, --OC(O)--, --C(O)O--, --C(O)C(O)--O--, --O--C(O)C(O)--, --C(O)NH--, --NHC(O)--, --OC(O)NH--, --NHC(O)O--, --NH--C(O)--NH--, --S(O) 2 NH--, --NHS(O) 2 --, --N(R 27 )--, --C(NR 27 )NHNH-- and --NHNHC(NR 27 )-- wherein R 27 is hydrogen, C 1 -C 10 -loweralkyl, aryl or heterocyclic, (v) C 3 -C 10 -cycloalkyl, (vi) aryl, (vii) heterocyclic, (viii) --N(R 28 )(R 29 ) wherein R 28 and R 29 are independently selected from hydrogen, C 1 -C 10 -loweralkyl, hydroxy-C 1 -C 10 -alkyl, aryl and heterocyclic, (ix) guanidino, (x) --S(O) 2 R 11 wherein R 11 is C 1 -C 10 -loweralkyl, aryl or aryl-C 1 -C 10 -alkyl, (xi) --OS(O) 2 R 11 wherein R 11 is defined as above, (xii) --SO 3 H, (xiii) --S(O) 2 NH 2 , (xiv) --SR 28 wherein R 28 is defined as above, (xv) halogen, (xvi) oxo and (xvii) epoxy; (f) --N(R a )(R b ) wherein R a and R b are independently selected from hydrogen, C 1 -C 10 -loweralkyl and --N(R c )(R d ) wherein R c and R d are independently selected from hydrogen and C 1 -C 10 -loweralkyl or (g) --OR* wherein R* is defined as above; R 10a is hydrogen and R 10b is hydrogen, hydroxy, protected hydroxy, C 1 -C 10 -alkoxy, C 2 -C 10 -alkenyl, C 2 -C 10 -alkenyloxy, halogen or --SR 28 wherein R 28 is independently defined as above or R 10b is hydrogen and R 10a is hydrogen, hydroxy, protected hydroxy, C 1 -C 10 -alkoxy, C 2 -C 10 -alkenyl, C 2 -C 10 -alkenyloxy, halogen or --SR 28 wherein R 28 is independently defined as above or R 10a and R 10b are both alkoxy or --SR 28a wherein R 28a is C 1 -C 10 -loweralkyl, aryl or heterocyclic or R 10a and R 10b taken together are oxo; and X is hydrogen and Y is hydrogen, hydroxy or protected hydroxy or Y is hydrogen and X is hydroxy or protected hydroxy or X and Y taken together are oxo wherein at each occurrence the term "aryl" is independently selected from phenyl, naphthyl, fluorenyl, (1,2,3,4-)-tetrahydronaphthyl, indenyl and indanyl which is either unsubstituted or substituted with one, two, or three substituents independently selected from the group consisting of C 1 -C 10 -loweralkyl, halo, halo-C 1 -C 10 -loweralkyl, halo-C 1 -C 10 -alkoxy, C 2 -C 10 -alkenyloxy, C 1 -C 10 -alkoxy, alkoxy-C 1 -C 10 -alkoxy, C 1 -C 10 -alkoxycarbonyl, C 1 -C 10 -alkoxycarbonylalkenyl, (C 1 -C 10 -alkoxycarbonyl )thio-C 1 -C 10 -alkoxy, thio-C 1 -C 10 -alkoxy, amino, C 1 -C 10 -alkylamino, C 1 -C 10 -dialkylamino, aminocarbonyl, aminocarbonyl-C 1 -C 10 -alkoxy, alkanoylamino, aryl-C 1 -C 10 -alkoxy, aryloxy, mercapto, nitro, carboxaldehyde, carboxy, carboxy-C 2 -C 10 -alkenyl, carboxy-C 1 -C 10 -alkoxy, C 1 -C 10 -alkylsulfonylamino, cyano-C 1 -C 10 -alkoxy, (heterocyclic)-C 1 -C 10 -alkoxy, hydroxy, hydroxy-C 1 -C 10 -alkoxy, phenyl, phenyl-substituted C 2 -C 10 -alkenyl, phenyl-substituted C 2 -C 10 -alkynyl, heterocyclic, --S(O) 2 NH 2 , tetrazolyl-C 1 -C 10 -alkoxy, tetrafluorophenyl and pentafluorophenyl and at each occurrence the term "heterocyclic" is independently selected from indolyl, quinolyl, isoquinolyl, tetrahydroquinolyl, benzofuryl, dihydrobenzofuryl, benzothienyl, azetidinyl, oxetanyl, pyrrolyl, pyrrolinyl, pyrrolidinyl, pyrazolyl, pyrazolinyl, pyrazolidinyl, imidazolyl, imidazolinyl, imidazolidinyl, pyridyl, piperidinyl, homopiperidinyl, pyrazinyl, piperazinyl, pyrimidinyl, pyridazinyl, oxazolyl, oxazolidinyl, isoxazolyl, isoxazolidinyl, morpholinyl, thiomorpholinyl, thiazolyl, thiazolidinyl, isothiazolyl, isothiazolidinyl, indolyl, quinolinyl, isoquinolinyl, benzimidazolyl, benzothiazolyl, benzoxazolyl, furyl, thienyl, thiazolidinyl, isothiazolyl, triazolyl, tetrazolyl, isoxazolyl, oxadiazolyl, thiadiazolyl, pyrrolyl, pyrimidyl, benzothienyl, compounds of the formula ##STR25## where X* is --CH 2 -- or --O-- and Y* is --C(O)-- or --C(R") 2 --! v where R" is hydrogen or C 1 -C 4 -alkyl and v is 1, 2 or 3, pyridin-2-on-1-yl, pyridin-4-on-1-yl, D-allose, D-altrose, D-glucose, D-mannose, D-gulose, D-idose, D-galactose, D-talose, D-ribose, D-arabinose, D-xylose, and D-lyxose wherein said heterocyclics are either unsubstituted or monosubstituted or disubstituted with substituents independently selected from hydroxy, halo, oxo (═O), amino, C 1 -C 10 -alkylamino, C 1 -C 10 -dialkylamino, C 1 -C 10 -alkoxy, alkoxy-C 1 -C 10 -alkoxy, alkoxy-C 1 -C 10 -alkyl, halo-C 1 -C 10 -alkyl, hydroxy, hydroxy-C 1 -C 10 -alkyl, C 3 -C 10 -cycloalkyl, aryl, aryl-C 1 -C 10 -alkyl, --COOH, --SO 3 H, --C(O)NH 2 and C 1 -C 10 -loweralkyl.
Claim 7
Independent Claim
1769 words
A method of immunomodulatory treatment comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compound having the formula: ##STR26## or a pharmaceutically acceptable salt, ester, amide or prodrug thereof wherein Z is ##STR27## R 1 is hydrogen, a hydroxy protecting group, C 1 -C 10 -loweralkyl or phenyl-substituted C 1 -C 10 -loweralkyl; R 2 is hydrogen and R 3 is hydroxy or protected hydroxy or R 2 and R 3 taken together are oxo; R 4 is hydrogen or phenyl-substituted C 1 -C 10 -loweralkyl and R 5 is hydroxy or protected hydroxy or R 5 is hydrogen or phenyl-substituted C 1 -C 10 -loweralkyl and R 4 is hydroxy or protected hydroxy or R 4 and R 5 taken together are oxo; R 6 is hydrogen or phenyl-substituted C 1 -C 10 -loweralkyl and R 7 is hydrogen, hydroxy or protected hydroxy or R 7 is hydrogen or phenyl-substituted C 1 -C 10 -loweralkyl and R 6 is hydroxy or protected hydroxy or R 6 and R 7 taken together are (1) oxo, (2) diazo, (3) ═CH 2 (4) --O--(CH 2 ) 2 --O--, (5) --S--(CH 2 ) 2 --S--, (6) --O--(CH 2 ) 3 --O--, (7) --S--(CH 2 ) 3 --S--, (8) ═N--OR 20 wherein R 20 is hydrogen, C 1 -C 10 -loweralkyl, C 2 -C 10 -alkenyl, C 3 -C 10 -cycloalkyl, C 3 -C 10 -cycloalkenyl, C 3 -C 10 -bicycloalkenyl, aryl, aryl-C 1 -C 10 -alkyl, heterocyclic or heterocyclic-C 1 -C 10 -alkyl, each of which is optionally substituted with C 1 -C 10 -loweralkyl, halogen, hydroxy, aryl or heterocyclic; or (9) ═N--N(R 21 )(R 22 ) wherein R 21 and R 22 are independently selected from hydrogen, C 1 -C 10 -loweralkyl, aryl, aryl-C 1 -C 10 -alkyl, heterocyclic and heterocyclic-C 1 -C 10 -alkyl; R 8 , R 9 , R 18 and R 19 are independently selected from (1) hydrogen, (2) --OS(O) 2 CF 3 , (3) --OS(O) 2 F, (4) --OS(O) 2 R 21a wherein R 21a is C 1 -C 10 -loweralkyl, aryl, aryl-C 1 -C 10 -alkyl, heterocyclic or heterocyclic-C 1 -C 10 -alkyl, (5) --OC(O)R 23 wherein R 23 is --O-aryl, --O--(N-succinimidyl), --O-benzotriazolyl, --O-2'-pyridyl or 5-tetrazolyl; (6) --OC(O)--N(R 24 )(R 25 ) wherein R 24 and R 25 are independently selected from (a) hydrogen, (b) C 1 -C 10 -loweralkyl, (c) C 2 -C 10 -alkenyl, (d) C 2 -C 10 -alkynyl, (e) C 3 -C 10 -cycloalkyl, (f) substituted C 1 -C 10 -loweralkyl, substituted C 2 -C 10 -alkenyl, substituted C 2 -C 10 -alkynyl or substituted C 3 -C 10 -cycloalkyl wherein the C 1 -C 10 -loweralkyl group, the C 2 -C 10 -alkenyl group, the C 2 -C 10 -alkynyl group or the C 3 -C 10 -cycloalkyl group is substituted by one or two substituents independently selected from (i) hydroxy, (ii) --COOH, (iii) --CN, (iv) --Q--(C 1 -C 10 -loweralkyl), --Q-aryl, --Q-(aryl-C 1 -C 10 -alkyl), --Q-heterocyclic or --Q-(heterocyclic-C 1 -C 10 -alkyl) wherein Q is --O--, --S--, --S(O)--, --S(O) 2 --, --C(O)--, --OC(O)--, --C(O)O--, --C(O)C(O)--O--, --O--C(O)C(O)--, --C(O)NH--, --NHC(O)--, --OC(O)NH--, --NHC(O)O--, --NH--C(O)--NH--, --S(O) 2 NH--, --NHS(O) 2 --, --N(R 27 )--, --C(NR 27 )NHNH-- and --NHNHC(NR 27 )-- wherein R 27 is hydrogen, C 1 -C 10 -loweralkyl, aryl or heterocyclic, (v) C 3 -C 10 -cycloalkyl, (vi) aryl, (vii) heterocyclic, (viii) --N(R 28 )(R 29 ) wherein R 28 and R 29 are independently selected from hydrogen, C 1 -C 10 -loweralkyl, hydroxy-C 1 -C 10 -alkyl, aryl and heterocyclic, (ix) guanidino, (x) --S(O) 2 R 11 wherein R 11 is C 1 -C 10 -loweralkyl, aryl or aryl-C 1 -C 10 -alkyl, (xi) --OS(O) 2 R 11 wherein R 11 is defined as above, (xii) --SO 3 H, (xiii) --S(O) 2 NH 2 , (xiv) --SR 28 wherein R 28 is defined as above, (xv) halogen, (xvi) oxo and (xvii) epoxy; (g) aryl, (h) heterocyclic, (i) --NHC(O)--O--(C 1 -C 10 -loweralkyl), (j) --NHC(O)-aryl, (k) --NHC(O)-heterocyclic and (l) C 1 -C 10 -loweralkyl substituted by --OC(O)--R f wherein R f is C 3 -C 10 -carboxyalkyl or --N(R 24 )(R 25 ) taken together form a nitrogen-containing heterocyclic group, (7) --OR 25 wherein R 25 is as defined above, (8) a protected hydroxy group, (9) --OC(O)N(OR 24 )(R 25 ) wherein R 24 and R 25 are defined as above, (10) --O(CH 2 ) i C(O)OR 20 wherein i is one or two and R 20 is independently defined as above, (11) --O(CH(Si(CH 3 ) 3 ))--(CH 2 ) j C(O)OR 20 wherein j is zero or one and R 20 is independently defined as above, (12) --O(CH 2 ) i C(O)N(R 24 )(R 25 ) wherein i, R 24 and R 25 are defined as above, (13) --O(CH 2 ) i C(O)N(OR 24 )(R 25 ) wherein i, R 24 and R 25 are defined as above, (14) --O(CH 2 ) i C(O)N(R 24 )(N(R 24 )(R 25 )) wherein i, R 24 and R 25 are defined as above, (15) --O(CH 2 ) i NHC(O)N(R 24 )(R 25 ) wherein i, R 24 and R 25 are defined as above, (16) --O(CH 2 ) i NHC(O)N(OR 24 )(R 25 ) wherein i, R 24 and R 25 are defined as above, (17) --O(CH 2 ) i NHC(O)N(R 24 )(N(R 24 )(R 25 )) wherein i, R 24 and R 25 are defined as above, (18) --OS(O) 2 N(R 24 )(R 25 ) wherein R 24 and R 25 are defined as above, (19) --O(CH 2 ) i --NHC(O)R 24 wherein R 24 is defined as above, (20) --OCH(R 24 )--SH wherein R 24 is defined as above, (21) --OCH(R 24 )--S--(C 1 -C 10 -loweralkyl) wherein R 24 is defined as above, (22) --OCH(R 24 )--S-aryl wherein R 24 is defined as above, (23) --N 3 , (24) --N═C═O, (25) --N(R 24 )(R 25 ) wherein R 24 and R 25 are defined as above, (26) --NHC(O)--R 24 wherein R 24 is defined as above, (27) --NHC(O)--N(R 24 )(R 25 ) wherein R 24 and R 25 are defined as above, (28) --S--R 24 wherein R 24 is defined as above and (29) --S--q--R 24 wherein q is a divalent radical selected from the group consisting of --S--, --C(O)--, --C(O)--O--, --C(O)--NH-- and --C(N(R 27 ))--NHNH-- and R 24 and R 27 are defined as above, with the proviso that one of R 8 and R 9 is hydrogen and the other is not hydrogen and one of R 18 and R 19 is hydrogen and the other is not hydrogen; or R 8 and R 9 taken together are (1) oxo, (2) ═N--O--R 24 wherein R 24 is defined as above or (3) ═N--N(R 24 )(R 25 ) wherein R 24 and R 25 are defined as above; or R 18 and R 19 taken together are (1) oxo, (2) ═N--O--R 24 wherein R 24 is independently defined as above or (3) ═N--N(R 24 )(R 25 ) wherein R 24 and R 25 are independently defined as above; or one of R 8 and R 9 taken together with one of R 18 and R 19 form a heterocyclic ring with the others of R 8 , R 9 , R 18 and R 19 being hydrogen or together forming a bond; or R 8 and R 18 are hydrogen and R 8 ' and R 19 form a bond; R 10a is hydrogen and R 10b is hydrogen, hydroxy, protected hydroxy, C 1 -C 10 -alkoxy, C 2 -C 10 -alkenyl, C 2 -C 10 -alkenyloxy, halogen or --SR 28 wherein R 28 is independently defined as above or R 10b is hydrogen and R 10a is hydrogen, hydroxy, protected hydroxy, C 1 --C 10 -alkoxy, C 2 --C 10 -alkenyl, C 2 --C 10 -alkenyloxy, halogen or --SR 28 wherein R 28 is independently defined as above or R 10a and R 10b are both alkoxy or --SR 28a wherein R 28a is C 1 -C 10 -loweralkyl, aryl or heterocyclic or R 10a and R 10b taken together are oxo; and X is hydrogen and Y is hydrogen, hydroxy or protected hydroxy or Y is hydrogen and X is hydroxy or protected hydroxy or X and Y taken together are oxo wherein at each occurrence the term "aryl" is independently selected from phenyl, naphthyl, fluorenyl, (1,2,3,4-)-tetrahydronaphthyl, indenyl and indanyl which is either unsubstituted or substituted with one, two, or three substituents independently selected from the group consisting of C 1 -C 10 -loweralkyl, halo, halo-C 1 -C 10 -loweralkyl, halo-C 1 -C 10 -alkoxy, C 2 -C 10 -alkenyloxy, C 1 -C 10 -alkoxy, alkoxy-C 1 -C 10 -alkoxy, C 1 -C 10 -alkoxycarbonyl, C 1 -C 10 -alkoxycarbonylalkenyl, (C 1 -C 10 -alkoxycarbonyl)thio-C 1 -C 10 -alkoxy, thio-C 1 -C 10 -alkoxy, amino, C 1 -C 10 -alkylamino, C 1 -C 10 -dialkylamino, aminocarbonyl, aminocarbonyl-C 1 -C 10 -alkoxy, alkanoylamino, aryl-C 1 -C 10 -alkoxy, aryloxy, mercapto, nitro, carboxaldehyde, carboxy, carboxy-C 2 -C 10 -alkenyl, carboxy-C 1 -C 10 -alkoxy, C 1 -C 10 -alkylsulfonylamino, cyano-C 1 -C 10 -alkoxy, (heterocyclic)-C 1 -C 10 -alkoxy, hydroxy, hydroxy-C 1 -C 10 -alkoxy, phenyl, phenyl-substituted C 2 -C 10 -alkenyl, phenyl-substituted C 2 -C 10 -alkynyl, heterocyclic, --S(O) 2 NH 2 , tetrazolyl-C 1 -C 10 -alkoxy, tetrafluorophenyl and pentafluorophenyl and at each occurrence the term "heterocyclic" is independently selected from indolyl, quinolyl, isoquinolyl, tetrahydroquinolyl, benzofuryl, dihydrobenzofuryl, benzothienyl, azetidinyl, oxetanyl, pyrrolyl, pyrrolinyl, pyrrolidinyl, pyrazolyl, pyrazolinyl, pyrazolidinyl, imidazolyl, imidazolinyl, imidazolidinyl, pyridyl, piperidinyl, homopiperidinyl, pyrazinyl, piperazinyl, pyrimidinyl, pyridazinyl, oxazolyl, oxazolidinyl, isoxazolyl, isoxazolidinyl, morpholinyl, thiomorpholinyl, thiazolyl, thiazolidinyl, isothiazolyl, isothiazolidinyl, indolyl, quinolinyl, isoquinolinyl, benzimidazolyl, benzothiazolyl, benzoxazolyl, furyl, thienyl, thiazolidinyl, isothiazolyl, triazolyl, tetrazolyl, isoxazolyl, oxadiazolyl, thiadiazolyl, pyrrolyl, pyrimidyl, benzothienyl, compounds of the formula ##STR28## where X* is --CH 2 -- or --O-- and Y* is --C(O)-- or --C(R") 2 --! v where R" is hydrogen or C 1 -C 4 -alkyl and v is 1, 2 or 3, pyridin-2-on-1-yl, pyridin-4-on-1-yl, D-allose, D-altrose, D-glucose, D-mannose, D-gulose, D-idose, D-galactose, D-talose, D-ribose, D-arabinose, D-xylose, and D-lyxose wherein said heterocyclics are either unsubstituted or monosubstituted or disubstituted with substituents independently selected from hydroxy, halo, oxo (═O), amino, C 1 -C 10 -alkylamino, C 1 -C 10 -dialkylamino, C 1 -C 10 -alkoxy, alkoxy-C 1 -C 10 -alkoxy, alkoxy-C 1 -C 10 -alkyl, halo-C 1 -C 10 -alkyl, hydroxy, hydroxy-C 1 -C 10 -alkyl, C 3 -C 10 -cycloalkyl, aryl, aryl-C 1 -C 10 -alkyl, --COOH, --SO 3 H, --C(O)NH 2 and C 1 -C 10 -loweralkyl.
Claim 8
Independent Claim
1769 words
A method of immunomodulatory treatment comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compound having the formula: ##STR26## or a pharmaceutically acceptable salt, ester, amide or prodrug thereof wherein Z is ##STR27## R 1 is hydrogen, a hydroxy protecting group, C 1 -C 10 -loweralkyl or phenyl-substituted C 1 -C 10 -loweralkyl; R 2 is hydrogen and R 3 is hydroxy or protected hydroxy or R 2 and R 3 taken together are oxo; R 4 is hydrogen or phenyl-substituted C 1 -C 10 -loweralkyl and R 5 is hydroxy or protected hydroxy or R 5 is hydrogen or phenyl-substituted C 1 -C 10 -loweralkyl and R 4 is hydroxy or protected hydroxy or R 4 and R 5 taken together are oxo; R 6 is hydrogen or phenyl-substituted C 1 -C 10 -loweralkyl and R 7 is hydrogen, hydroxy or protected hydroxy or R 7 is hydrogen or phenyl-substituted C 1 -C 10 -loweralkyl and R 6 is hydroxy or protected hydroxy or R 6 and R 7 taken together are (1) oxo, (2) diazo, (3) ═CH 2 (4) --O--(CH 2 ) 2 --O--, (5) --S--(CH 2 ) 2 --S--, (6) --O--(CH 2 ) 3 --O--, (7) --S--(CH 2 ) 3 --S--, (8) ═N--OR 20 wherein R 20 is hydrogen, C 1 -C 10 -loweralkyl, C 2 -C 10 -alkenyl, C 3 -C 10 -cycloalkyl, C 3 -C 10 -cycloalkenyl, C 3 -C 10 -bicycloalkenyl, aryl, aryl-C 1 -C 10 -alkyl, heterocyclic or heterocyclic-C 1 -C 10 -alkyl, each of which is optionally substituted with C 1 -C 10 -loweralkyl, halogen, hydroxy, aryl or heterocyclic; or (9) ═N--N(R 21 )(R 22 ) wherein R 21 and R 22 are independently selected from hydrogen, C 1 -C 10 -loweralkyl, aryl, aryl-C 1 -C 10 -alkyl, heterocyclic and heterocyclic-C 1 -C 10 -alkyl; R 8 , R 9 , R 18 and R 19 are independently selected from (1) hydrogen, (2) --OS(O) 2 CF 3 , (3) --OS(O) 2 F, (4) --OS(O) 2 R 21a wherein R 21a is C 1 -C 10 -loweralkyl, aryl, aryl-C 1 -C 10 -alkyl, heterocyclic or heterocyclic-C 1 -C 10 -alkyl, (5) --OC(O)R 23 wherein R 23 is --O-aryl, --O--(N-succinimidyl), --O-benzotriazolyl, --O-2'-pyridyl or 5-tetrazolyl; (6) --OC(O)--N(R 24 )(R 25 ) wherein R 24 and R 25 are independently selected from (a) hydrogen, (b) C 1 -C 10 -loweralkyl, (c) C 2 -C 10 -alkenyl, (d) C 2 -C 10 -alkynyl, (e) C 3 -C 10 -cycloalkyl, (f) substituted C 1 -C 10 -loweralkyl, substituted C 2 -C 10 -alkenyl, substituted C 2 -C 10 -alkynyl or substituted C 3 -C 10 -cycloalkyl wherein the C 1 -C 10 -loweralkyl group, the C 2 -C 10 -alkenyl group, the C 2 -C 10 -alkynyl group or the C 3 -C 10 -cycloalkyl group is substituted by one or two substituents independently selected from (i) hydroxy, (ii) --COOH, (iii) --CN, (iv) --Q--(C 1 -C 10 -loweralkyl), --Q-aryl, --Q-(aryl-C 1 -C 10 -alkyl), --Q-heterocyclic or --Q-(heterocyclic-C 1 -C 10 -alkyl) wherein Q is --O--, --S--, --S(O)--, --S(O) 2 --, --C(O)--, --OC(O)--, --C(O)O--, --C(O)C(O)--O--, --O--C(O)C(O)--, --C(O)NH--, --NHC(O)--, --OC(O)NH--, --NHC(O)O--, --NH--C(O)--NH--, --S(O) 2 NH--, --NHS(O) 2 --, --N(R 27 )--, --C(NR 27 )NHNH-- and --NHNHC(NR 27 )-- wherein R 27 is hydrogen, C 1 -C 10 -loweralkyl, aryl or heterocyclic, (v) C 3 -C 10 -cycloalkyl, (vi) aryl, (vii) heterocyclic, (viii) --N(R 28 )(R 29 ) wherein R 28 and R 29 are independently selected from hydrogen, C 1 -C 10 -loweralkyl, hydroxy-C 1 -C 10 -alkyl, aryl and heterocyclic, (ix) guanidino, (x) --S(O) 2 R 11 wherein R 11 is C 1 -C 10 -loweralkyl, aryl or aryl-C 1 -C 10 -alkyl, (xi) --OS(O) 2 R 11 wherein R 11 is defined as above, (xii) --SO 3 H, (xiii) --S(O) 2 NH 2 , (xiv) --SR 28 wherein R 28 is defined as above, (xv) halogen, (xvi) oxo and (xvii) epoxy; (g) aryl, (h) heterocyclic, (i) --NHC(O)--O--(C 1 -C 10 -loweralkyl), (j) --NHC(O)-aryl, (k) --NHC(O)-heterocyclic and (l) C 1 -C 10 -loweralkyl substituted by --OC(O)--R f wherein R f is C 3 -C 10 -carboxyalkyl or --N(R 24 )(R 25 ) taken together form a nitrogen-containing heterocyclic group, (7) --OR 25 wherein R 25 is as defined above, (8) a protected hydroxy group, (9) --OC(O)N(OR 24 )(R 25 ) wherein R 24 and R 25 are defined as above, (10) --O(CH 2 ) i C(O)OR 20 wherein i is one or two and R 20 is independently defined as above, (11) --O(CH(Si(CH 3 ) 3 ))--(CH 2 ) j C(O)OR 20 wherein j is zero or one and R 20 is independently defined as above, (12) --O(CH 2 ) i C(O)N(R 24 )(R 25 ) wherein i, R 24 and R 25 are defined as above, (13) --O(CH 2 ) i C(O)N(OR 24 )(R 25 ) wherein i, R 24 and R 25 are defined as above, (14) --O(CH 2 ) i C(O)N(R 24 )(N(R 24 )(R 25 )) wherein i, R 24 and R 25 are defined as above, (15) --O(CH 2 ) i NHC(O)N(R 24 )(R 25 ) wherein i, R 24 and R 25 are defined as above, (16) --O(CH 2 ) i NHC(O)N(OR 24 )(R 25 ) wherein i, R 24 and R 25 are defined as above, (17) --O(CH 2 ) i NHC(O)N(R 24 )(N(R 24 )(R 25 )) wherein i, R 24 and R 25 are defined as above, (18) --OS(O) 2 N(R 24 )(R 25 ) wherein R 24 and R 25 are defined as above, (19) --O(CH 2 ) i --NHC(O)R 24 wherein R 24 is defined as above, (20) --OCH(R 24 )--SH wherein R 24 is defined as above, (21) --OCH(R 24 )--S--(C 1 -C 10 -loweralkyl) wherein R 24 is defined as above, (22) --OCH(R 24 )--S-aryl wherein R 24 is defined as above, (23) --N 3 , (24) --N═C═O, (25) --N(R 24 )(R 25 ) wherein R 24 and R 25 are defined as above, (26) --NHC(O)--R 24 wherein R 24 is defined as above, (27) --NHC(O)--N(R 24 )(R 25 ) wherein R 24 and R 25 are defined as above, (28) --S--R 24 wherein R 24 is defined as above and (29) --S--q--R 24 wherein q is a divalent radical selected from the group consisting of --S--, --C(O)--, --C(O)--O--, --C(O)--NH-- and --C(N(R 27 ))--NHNH-- and R 24 and R 27 are defined as above, with the proviso that one of R 8 and R 9 is hydrogen and the other is not hydrogen and one of R 18 and R 19 is hydrogen and the other is not hydrogen; or R 8 and R 9 taken together are (1) oxo, (2) ═N--O--R 24 wherein R 24 is defined as above or (3) ═N--N(R 24 )(R 25 ) wherein R 24 and R 25 are defined as above; or R 18 and R 19 taken together are (1) oxo, (2) ═N--O--R 24 wherein R 24 is independently defined as above or (3) ═N--N(R 24 )(R 25 ) wherein R 24 and R 25 are independently defined as above; or one of R 8 and R 9 taken together with one of R 18 and R 19 form a heterocyclic ring with the others of R 8 , R 9 , R 18 and R 19 being hydrogen or together forming a bond; or R 8 and R 18 are hydrogen and R 8 ' and R 19 form a bond; R 10a is hydrogen and R 10b is hydrogen, hydroxy, protected hydroxy, C 1 -C 10 -alkoxy, C 2 -C 10 -alkenyl, C 2 -C 10 -alkenyloxy, halogen or --SR 28 wherein R 28 is independently defined as above or R 10b is hydrogen and R 10a is hydrogen, hydroxy, protected hydroxy, C 1 --C 10 -alkoxy, C 2 --C 10 -alkenyl, C 2 --C 10 -alkenyloxy, halogen or --SR 28 wherein R 28 is independently defined as above or R 10a and R 10b are both alkoxy or --SR 28a wherein R 28a is C 1 -C 10 -loweralkyl, aryl or heterocyclic or R 10a and R 10b taken together are oxo; and X is hydrogen and Y is hydrogen, hydroxy or protected hydroxy or Y is hydrogen and X is hydroxy or protected hydroxy or X and Y taken together are oxo wherein at each occurrence the term "aryl" is independently selected from phenyl, naphthyl, fluorenyl, (1,2,3,4-)-tetrahydronaphthyl, indenyl and indanyl which is either unsubstituted or substituted with one, two, or three substituents independently selected from the group consisting of C 1 -C 10 -loweralkyl, halo, halo-C 1 -C 10 -loweralkyl, halo-C 1 -C 10 -alkoxy, C 2 -C 10 -alkenyloxy, C 1 -C 10 -alkoxy, alkoxy-C 1 -C 10 -alkoxy, C 1 -C 10 -alkoxycarbonyl, C 1 -C 10 -alkoxycarbonylalkenyl, (C 1 -C 10 -alkoxycarbonyl)thio-C 1 -C 10 -alkoxy, thio-C 1 -C 10 -alkoxy, amino, C 1 -C 10 -alkylamino, C 1 -C 10 -dialkylamino, aminocarbonyl, aminocarbonyl-C 1 -C 10 -alkoxy, alkanoylamino, aryl-C 1 -C 10 -alkoxy, aryloxy, mercapto, nitro, carboxaldehyde, carboxy, carboxy-C 2 -C 10 -alkenyl, carboxy-C 1 -C 10 -alkoxy, C 1 -C 10 -alkylsulfonylamino, cyano-C 1 -C 10 -alkoxy, (heterocyclic)-C 1 -C 10 -alkoxy, hydroxy, hydroxy-C 1 -C 10 -alkoxy, phenyl, phenyl-substituted C 2 -C 10 -alkenyl, phenyl-substituted C 2 -C 10 -alkynyl, heterocyclic, --S(O) 2 NH 2 , tetrazolyl-C 1 -C 10 -alkoxy, tetrafluorophenyl and pentafluorophenyl and at each occurrence the term "heterocyclic" is independently selected from indolyl, quinolyl, isoquinolyl, tetrahydroquinolyl, benzofuryl, dihydrobenzofuryl, benzothienyl, azetidinyl, oxetanyl, pyrrolyl, pyrrolinyl, pyrrolidinyl, pyrazolyl, pyrazolinyl, pyrazolidinyl, imidazolyl, imidazolinyl, imidazolidinyl, pyridyl, piperidinyl, homopiperidinyl, pyrazinyl, piperazinyl, pyrimidinyl, pyridazinyl, oxazolyl, oxazolidinyl, isoxazolyl, isoxazolidinyl, morpholinyl, thiomorpholinyl, thiazolyl, thiazolidinyl, isothiazolyl, isothiazolidinyl, indolyl, quinolinyl, isoquinolinyl, benzimidazolyl, benzothiazolyl, benzoxazolyl, furyl, thienyl, thiazolidinyl, isothiazolyl, triazolyl, tetrazolyl, isoxazolyl, oxadiazolyl, thiadiazolyl, pyrrolyl, pyrimidyl, benzothienyl, compounds of the formula ##STR28## where X* is --CH 2 -- or --O-- and Y* is --C(O)-- or --C(R") 2 --! v where R" is hydrogen or C 1 -C 4 -alkyl and v is 1, 2 or 3, pyridin-2-on-1-yl, pyridin-4-on-1-yl, D-allose, D-altrose, D-glucose, D-mannose, D-gulose, D-idose, D-galactose, D-talose, D-ribose, D-arabinose, D-xylose, and D-lyxose wherein said heterocyclics are either unsubstituted or monosubstituted or disubstituted with substituents independently selected from hydroxy, halo, oxo (═O), amino, C 1 -C 10 -alkylamino, C 1 -C 10 -dialkylamino, C 1 -C 10 -alkoxy, alkoxy-C 1 -C 10 -alkoxy, alkoxy-C 1 -C 10 -alkyl, halo-C 1 -C 10 -alkyl, hydroxy, hydroxy-C 1 -C 10 -alkyl, C 3 -C 10 -cycloalkyl, aryl, aryl-C 1 -C 10 -alkyl, --COOH, --SO 3 H, --C(O)NH 2 and C 1 -C 10 -loweralkyl.
Claim 9
Independent Claim
1218 words
A method of immunomodulatory treatment comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compound having the formula: ##STR29## or a pharmaceutically acceptable salt, ester, amide or prodrug thereof wherein R 1 is hydrogen, a hydroxy protecting group, C 1 -C 10 -loweralkyl or phenyl-substituted C 1 -C 10 -loweralkyl; R 2 is hydrogen and R 3 is hydroxy or protected hydroxy or R 2 and R 3 taken together are oxo; R 4 is hydrogen or phenyl-substituted C 1 -C 10 -loweralkyl and R 5 is hydroxy or protected hydroxy or R 5 is hydrogen or phenyl-substituted C 1 -C 10 -loweralkyl and R 4 is hydroxy or protected hydroxy or R 4 and R 5 taken together are oxo; R 6 is hydrogen or phenyl-substituted C 1 -C 10 -loweralkyl and R 7 is hydrogen, hydroxy or protected hydroxy or R 7 is hydrogen or phenyl-substituted C 1 -C 10 -loweralkyl and R 6 is hydroxy or protected hydroxy or R 6 and R 7 taken together are (1) oxo, (2) diazo, (3) ═CH 2 (4) --O--(CH 2 ) 2 --O--, (5) --S--(CH 2 ) 2 --S--, (6) --O--(CH 2 ) 3 --O--, (7) --S--(CH 2 ) 3 --S--, (8) ═N--OR 20 wherein R 20 is hydrogen, C 1 -C 10 -loweralkyl, C 2 -C 10 -alkenyl, C 3 -C 10 -cycloalkyl, C 3 -C 10 -cycloalkenyl, C 3 -C 10 -bicycloalkenyl, aryl, aryl-C 1 -C 10 -alkyl, heterocyclic or heterocyclic-C 1 -C 10 -alkyl, each of which is optionally substituted with C 1 -C 10 -loweralkyl, halogen, hydroxy, aryl or heterocyclic; or (9) ═N--N(R 21 )(R 22 ) wherein R 21 and R 22 are independently selected from hydrogen, C 1 -C 10 -loweralkyl, aryl, aryl-C 1 -C 10 -alkyl, heterocyclic and heterocyclic-C 1 -C 10 -alkyl; R 8 is (1) --OC(O)N(OR 20 )(R 24 ) or (2) --O--C(O)--NHN(R 24 )(R 25 ) wherein R 20 is hydrogen, C 1 -C 10 -loweralkyl, C 2 -C 10 -alkenyl, C 3 -C 10 -cycloalkyl, C 3 -C 10 -cycloalkenyl, C 3 -C 10 -bicycloalkenyl, aryl or heterocyclic, each of which is optionally substituted with C 1 -C 10 -loweralkyl, hydroxy, aryl or heterocyclic and R 24 and R 25 are independently selected from (a) hydrogen, (b) C 1 -C 10 -loweralkyl, (c) C 2 -C 10 -alkenyl, (d) C 2 -C 10 -alkynyl, (e) C 3 -C 10 -cycloalkyl, (f) substituted C 1 -C 10 -loweralkyl, substituted C 2 -C 10 -alkenyl, substituted C 2 -C 10 -alkynyl or substituted C 3 -C 10 -cycloalkyl wherein the C 1 -C 10 -loweralkyl group, the C 2 -C 10 -alkenyl group, the C 2 -C 10 -alkynyl group or the C 3 -C 10 -cycloalkyl group is substituted by one or two substituents independently selected from (i) hydroxy, (ii) --COOH, (iii) --CN, (iv) --Q--C 1 -C 10 -loweralkyl, --Q-aryl, --Q-(aryl-C 1 -C 10 -alkyl), --Q-heterocyclic or --Q-(heterocyclicalkyl) wherein Q, is --O--, --S--, --S(O)--, --S(O) 2 --, --C(O)--, --OC(O)--, --C(O)O--, --C(O)C(O)--O--, --O--C(O)C(O)--, --C(O)NH--, --NHC(O)--, --OC(O)NH--, --NHC(O)O--, --NH--C(O)--NH--, --S(O) 2 NH--, --NHS(O) 2 --, --N(R 27 )--, --C(NR 27 )NHNH-- and --NHNHC(NR 27 )-- wherein R 27 is hydrogen, C 1 -C 10 -loweralkyl, aryl or heterocyclic, (v) C 3 -C 10 -cycloalkyl, (vi) aryl, (vii) heterocyclic, (viii) --N(R 28 )(R 29 ) R 28 and R 29 are independently selected from hydrogen, C 1 -C 10 -loweralkyl, hydroxy-C 1 -C 10 -alkyl, aryl and heterocyclic, (ix) guanidino, (x) --S(O) 2 R 11 wherein R 11 is C 1 -C 10 -loweralkyl, aryl or aryl-C 1 -C 10 -alkyl, (xi) --OS(O) 2 R 11 wherein R 11 is defined as above, (xii) --SO 3 H, (xiii) --S(O) 2 NH 2 , (xiv) --SR 28 wherein R 28 is defined as above, (xv) halogen, (xvi) oxo and (xvii) epoxy; (g) aryl, (h) heterocyclic, (i) --NHC(O)--O--(C 1 -C 10 -loweralkyl), (j) --NHC(O)-aryl, (k) --NHC(O)-heterocyclic or (l) C 1 -C 10 -loweralkyl substituted by --OC(O)--R f wherein R f is C 3 -C 10 -carboxyalkyl or --N(R 24 )(R 25 ) taken together form a nitrogen-containing heterocyclic group; R 9 is hydrogen; R 10a is hydrogen and R 10b is hydrogen, hydroxy, protected hydroxy, C 1 -C 10 -alkoxy, C 2 -C 10 -alkenyl, C 2 -C 10 -alkenyloxy, halogen or --SR 28 wherein R 28 is independently defined as above or R 10b is hydrogen and R 10a is hydrogen, hydroxy, protected hydroxy, C 1 -C 10 -alkoxy, C 2 -C 10 -alkenyl, C 2 -C 10 -alkenyloxy, halogen or --SR 28 wherein R 28 is independently defined as above or R 10a and R 10b are both C 1 -C 10 -alkoxy or --SR 28a wherein R 28a is C 1 -C 10 -loweralkyl, aryl or heterocyclic or R 10a and R 10b taken together are oxo; and X is hydrogen and Y is hydrogen, hydroxy or protected hydroxy or Y is hydrogen and X is hydroxy or protected hydroxy or X and Y taken together are oxo wherein at each occurrence the term "aryl" is independently selected from phenyl, naphthyl, fluorenyl, (1,2,3,4-)-tetrahydronaphthyl, indenyl and indanyl which is either unsubstituted or substituted with one, two, or three substituents independently selected from the group consisting of C 1 -C 10 -loweralkyl, halo, halo-C 1 -C 10 -loweralkyl, halo-C 1 -C 10 -alkoxy, C 2 -C 10 -alkenyloxy, C 1 -C 10 -alkoxy, alkoxy-C 1 -C 10 -alkoxy, C 1 --C 10 -alkoxycarbonyl, C 1 -C 10 -alkoxycarbonylalkenyl, (C 1 -C 10 -alkoxycarbonyl)thio-C 1 -C 10 -alkoxy, thio-C 1 -C 10 -alkoxy, amino, C 1 -C 10 -alkylamino, C 1 -C 10 -dialkylamino, aminocarbonyl, aminocarbonyl-C 1 -C 10 -alkoxy, alkanoylamino, aryl-C 1 -C 10 -alkoxy, aryloxy, mercapto, nitro, carboxaldehyde, carboxy, carboxy-C 2 -C 10 -alkenyl, carboxy-C 1 -C 10 -alkoxy, C 1 -C 10 -alkylsulfonylamino, cyano-C 1 -C 10 -alkoxy, (heterocyclic)-C 1 -C 10 -alkoxy, hydroxy, hydroxy-C 1 -C 10 -alkoxy, phenyl, phenyl-substituted C 2 -C 10 -alkenyl, phenyl-substituted C 2 -C 10 -alkynyl, heterocyclic, --S(O) 2 NH 2 , tetrazolyl-C 1 -C 10 -alkoxy, tetrafluorophenyl and pentafluorophenyl and at each occurrence the term "heterocyclic" is independently selected from indolyl, quinolyl, isoquinolyl, tetrahydroquinolyl, benzofuryl, dihydrobenzofuryl, benzothienyl, azetidinyl, oxetanyl, pyrrolyl, pyrrolinyl, pyrrolidinyl, pyrazolyl, pyrazolinyl, pyrazolidinyl, imidazolyl, imidazolinyl, imidazolidinyl, pyridyl, piperidinyl, homopiperidinyl, pyrazinyl, piperazinyl, pyrimidinyl, pyridazinyl, oxazolyl, oxazolidinyl, isoxazolyl, isoxazolidinyl, morpholinyl, thiomorpholinyl, thiazolyl, thiazolidinyl, isothiazolyl, isothiazolidinyl, indolyl, quinolinyl, isoquinolinyl, benzimidazolyl, benzothiazolyl, benzoxazolyl, furyl, thienyl, thiazolidinyl, isothiazolyl, triazolyl, tetrazolyl, isoxazolyl, oxadiazolyl, thiadiazolyl, pyrrolyl, pyrimidyl, benzothienyl, compounds of the formula ##STR30## where X* is --CH 2 -- or --O-- and Y* is --C(O)-- or --C(R") 2 --! v where R" is hydrogen or C 1 -C 4 -alkyl and v is 1, 2 or 3, pyridin-2-on-1-yl, pyridin-4-on-1-yl, D-allose, D-altrose, D-glucose, D-mannose, D-gulose, D-idose, D-galactose, D-talose, D-ribose, D-arabinose, D-xylose, and D-lyxose wherein said heterocyclics are either unsubstituted or monosubstituted or disubstituted with substituents independently selected from hydroxy, halo, oxo (═O), amino, C 1 -C 10 -alkylamino, C 1 -C 10 -dialkylamino, C 1 -C 10 -alkoxy, alkoxy-C 1 -C 10 -alkoxy, alkoxy-C 1 -C 10 -alkyl, halo-C 1 -C 10 -alkyl, hydroxy, hydroxy-C 1 -C 10 -alkyl, C 3 --C 10 -cycloalkyl, aryl, aryl-C 1 -C 10 -alkyl, --COOH, --SO 3 H, --C(O)NH 2 and C 1 -C 10 -loweralkyl.
Claim 10
Independent Claim
1218 words
A method of immunomodulatory treatment comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compound having the formula: ##STR29## or a pharmaceutically acceptable salt, ester, amide or prodrug thereof wherein R 1 is hydrogen, a hydroxy protecting group, C 1 -C 10 -loweralkyl or phenyl-substituted C 1 -C 10 -loweralkyl; R 2 is hydrogen and R 3 is hydroxy or protected hydroxy or R 2 and R 3 taken together are oxo; R 4 is hydrogen or phenyl-substituted C 1 -C 10 -loweralkyl and R 5 is hydroxy or protected hydroxy or R 5 is hydrogen or phenyl-substituted C 1 -C 10 -loweralkyl and R 4 is hydroxy or protected hydroxy or R 4 and R 5 taken together are oxo; R 6 is hydrogen or phenyl-substituted C 1 -C 10 -loweralkyl and R 7 is hydrogen, hydroxy or protected hydroxy or R 7 is hydrogen or phenyl-substituted C 1 -C 10 -loweralkyl and R 6 is hydroxy or protected hydroxy or R 6 and R 7 taken together are (1) oxo, (2) diazo, (3) ═CH 2 (4) --O--(CH 2 ) 2 --O--, (5) --S--(CH 2 ) 2 --S--, (6) --O--(CH 2 ) 3 --O--, (7) --S--(CH 2 ) 3 --S--, (8) ═N--OR 20 wherein R 20 is hydrogen, C 1 -C 10 -loweralkyl, C 2 -C 10 -alkenyl, C 3 -C 10 -cycloalkyl, C 3 -C 10 -cycloalkenyl, C 3 -C 10 -bicycloalkenyl, aryl, aryl-C 1 -C 10 -alkyl, heterocyclic or heterocyclic-C 1 -C 10 -alkyl, each of which is optionally substituted with C 1 -C 10 -loweralkyl, halogen, hydroxy, aryl or heterocyclic; or (9) ═N--N(R 21 )(R 22 ) wherein R 21 and R 22 are independently selected from hydrogen, C 1 -C 10 -loweralkyl, aryl, aryl-C 1 -C 10 -alkyl, heterocyclic and heterocyclic-C 1 -C 10 -alkyl; R 8 is (1) --OC(O)N(OR 20 )(R 24 ) or (2) --O--C(O)--NHN(R 24 )(R 25 ) wherein R 20 is hydrogen, C 1 -C 10 -loweralkyl, C 2 -C 10 -alkenyl, C 3 -C 10 -cycloalkyl, C 3 -C 10 -cycloalkenyl, C 3 -C 10 -bicycloalkenyl, aryl or heterocyclic, each of which is optionally substituted with C 1 -C 10 -loweralkyl, hydroxy, aryl or heterocyclic and R 24 and R 25 are independently selected from (a) hydrogen, (b) C 1 -C 10 -loweralkyl, (c) C 2 -C 10 -alkenyl, (d) C 2 -C 10 -alkynyl, (e) C 3 -C 10 -cycloalkyl, (f) substituted C 1 -C 10 -loweralkyl, substituted C 2 -C 10 -alkenyl, substituted C 2 -C 10 -alkynyl or substituted C 3 -C 10 -cycloalkyl wherein the C 1 -C 10 -loweralkyl group, the C 2 -C 10 -alkenyl group, the C 2 -C 10 -alkynyl group or the C 3 -C 10 -cycloalkyl group is substituted by one or two substituents independently selected from (i) hydroxy, (ii) --COOH, (iii) --CN, (iv) --Q--C 1 -C 10 -loweralkyl, --Q-aryl, --Q-(aryl-C 1 -C 10 -alkyl), --Q-heterocyclic or --Q-(heterocyclicalkyl) wherein Q, is --O--, --S--, --S(O)--, --S(O) 2 --, --C(O)--, --OC(O)--, --C(O)O--, --C(O)C(O)--O--, --O--C(O)C(O)--, --C(O)NH--, --NHC(O)--, --OC(O)NH--, --NHC(O)O--, --NH--C(O)--NH--, --S(O) 2 NH--, --NHS(O) 2 --, --N(R 27 )--, --C(NR 27 )NHNH-- and --NHNHC(NR 27 )-- wherein R 27 is hydrogen, C 1 -C 10 -loweralkyl, aryl or heterocyclic, (v) C 3 -C 10 -cycloalkyl, (vi) aryl, (vii) heterocyclic, (viii) --N(R 28 )(R 29 ) R 28 and R 29 are independently selected from hydrogen, C 1 -C 10 -loweralkyl, hydroxy-C 1 -C 10 -alkyl, aryl and heterocyclic, (ix) guanidino, (x) --S(O) 2 R 11 wherein R 11 is C 1 -C 10 -loweralkyl, aryl or aryl-C 1 -C 10 -alkyl, (xi) --OS(O) 2 R 11 wherein R 11 is defined as above, (xii) --SO 3 H, (xiii) --S(O) 2 NH 2 , (xiv) --SR 28 wherein R 28 is defined as above, (xv) halogen, (xvi) oxo and (xvii) epoxy; (g) aryl, (h) heterocyclic, (i) --NHC(O)--O--(C 1 -C 10 -loweralkyl), (j) --NHC(O)-aryl, (k) --NHC(O)-heterocyclic or (l) C 1 -C 10 -loweralkyl substituted by --OC(O)--R f wherein R f is C 3 -C 10 -carboxyalkyl or --N(R 24 )(R 25 ) taken together form a nitrogen-containing heterocyclic group; R 9 is hydrogen; R 10a is hydrogen and R 10b is hydrogen, hydroxy, protected hydroxy, C 1 -C 10 -alkoxy, C 2 -C 10 -alkenyl, C 2 -C 10 -alkenyloxy, halogen or --SR 28 wherein R 28 is independently defined as above or R 10b is hydrogen and R 10a is hydrogen, hydroxy, protected hydroxy, C 1 -C 10 -alkoxy, C 2 -C 10 -alkenyl, C 2 -C 10 -alkenyloxy, halogen or --SR 28 wherein R 28 is independently defined as above or R 10a and R 10b are both C 1 -C 10 -alkoxy or --SR 28a wherein R 28a is C 1 -C 10 -loweralkyl, aryl or heterocyclic or R 10a and R 10b taken together are oxo; and X is hydrogen and Y is hydrogen, hydroxy or protected hydroxy or Y is hydrogen and X is hydroxy or protected hydroxy or X and Y taken together are oxo wherein at each occurrence the term "aryl" is independently selected from phenyl, naphthyl, fluorenyl, (1,2,3,4-)-tetrahydronaphthyl, indenyl and indanyl which is either unsubstituted or substituted with one, two, or three substituents independently selected from the group consisting of C 1 -C 10 -loweralkyl, halo, halo-C 1 -C 10 -loweralkyl, halo-C 1 -C 10 -alkoxy, C 2 -C 10 -alkenyloxy, C 1 -C 10 -alkoxy, alkoxy-C 1 -C 10 -alkoxy, C 1 --C 10 -alkoxycarbonyl, C 1 -C 10 -alkoxycarbonylalkenyl, (C 1 -C 10 -alkoxycarbonyl)thio-C 1 -C 10 -alkoxy, thio-C 1 -C 10 -alkoxy, amino, C 1 -C 10 -alkylamino, C 1 -C 10 -dialkylamino, aminocarbonyl, aminocarbonyl-C 1 -C 10 -alkoxy, alkanoylamino, aryl-C 1 -C 10 -alkoxy, aryloxy, mercapto, nitro, carboxaldehyde, carboxy, carboxy-C 2 -C 10 -alkenyl, carboxy-C 1 -C 10 -alkoxy, C 1 -C 10 -alkylsulfonylamino, cyano-C 1 -C 10 -alkoxy, (heterocyclic)-C 1 -C 10 -alkoxy, hydroxy, hydroxy-C 1 -C 10 -alkoxy, phenyl, phenyl-substituted C 2 -C 10 -alkenyl, phenyl-substituted C 2 -C 10 -alkynyl, heterocyclic, --S(O) 2 NH 2 , tetrazolyl-C 1 -C 10 -alkoxy, tetrafluorophenyl and pentafluorophenyl and at each occurrence the term "heterocyclic" is independently selected from indolyl, quinolyl, isoquinolyl, tetrahydroquinolyl, benzofuryl, dihydrobenzofuryl, benzothienyl, azetidinyl, oxetanyl, pyrrolyl, pyrrolinyl, pyrrolidinyl, pyrazolyl, pyrazolinyl, pyrazolidinyl, imidazolyl, imidazolinyl, imidazolidinyl, pyridyl, piperidinyl, homopiperidinyl, pyrazinyl, piperazinyl, pyrimidinyl, pyridazinyl, oxazolyl, oxazolidinyl, isoxazolyl, isoxazolidinyl, morpholinyl, thiomorpholinyl, thiazolyl, thiazolidinyl, isothiazolyl, isothiazolidinyl, indolyl, quinolinyl, isoquinolinyl, benzimidazolyl, benzothiazolyl, benzoxazolyl, furyl, thienyl, thiazolidinyl, isothiazolyl, triazolyl, tetrazolyl, isoxazolyl, oxadiazolyl, thiadiazolyl, pyrrolyl, pyrimidyl, benzothienyl, compounds of the formula ##STR30## where X* is --CH 2 -- or --O-- and Y* is --C(O)-- or --C(R") 2 --! v where R" is hydrogen or C 1 -C 4 -alkyl and v is 1, 2 or 3, pyridin-2-on-1-yl, pyridin-4-on-1-yl, D-allose, D-altrose, D-glucose, D-mannose, D-gulose, D-idose, D-galactose, D-talose, D-ribose, D-arabinose, D-xylose, and D-lyxose wherein said heterocyclics are either unsubstituted or monosubstituted or disubstituted with substituents independently selected from hydroxy, halo, oxo (═O), amino, C 1 -C 10 -alkylamino, C 1 -C 10 -dialkylamino, C 1 -C 10 -alkoxy, alkoxy-C 1 -C 10 -alkoxy, alkoxy-C 1 -C 10 -alkyl, halo-C 1 -C 10 -alkyl, hydroxy, hydroxy-C 1 -C 10 -alkyl, C 3 --C 10 -cycloalkyl, aryl, aryl-C 1 -C 10 -alkyl, --COOH, --SO 3 H, --C(O)NH 2 and C 1 -C 10 -loweralkyl.
Claim 11
Independent Claim
1328 words
A method of immunomodulatory treatment comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compound having the formula: ##STR31## or a pharmaceutically acceptable salt, ester, amide or prodrug thereof wherein R 1 is hydrogen, a hydroxy protecting group, C 1 -C 10 -loweralkyl or phenyl-substituted C 1 -C 10 -loweralkyl; R 2 is hydrogen and R 3 is hydroxy or protected hydroxy or R 2 and R 3 taken together are oxo; R 4 is hydrogen or phenyl-substituted C 1 -C 10 -loweralkyl and R 5 is hydroxy or protected hydroxy or R 5 is hydrogen or phenyl-substituted C 1 -C 10 -loweralkyl and R 4 is hydroxy or protected hydroxy or R 4 and R 5 taken together are oxo; R 6 is hydrogen or phenyl-substituted C 1 -C 10 -loweralkyl and R 7 is hydrogen, hydroxy or protected hydroxy or R 7 is hydrogen or phenyl-substituted C 1 -C 10 -loweralkyl and R 6 is hydroxy or protected hydroxy or R 6 and R 7 taken together are (1) oxo, (2) diazo, (3) ═CH 2 (4) --O--(CH 2 ) 2 --O--, (5) --S--(CH 2 ) 2 --S--, (6) --O--(CH 2 ) 3 --O--, (7) --S--(CH 2 ) 3 --S--, (8) ═N--OR 20 wherein R 20 is hydrogen, C 1 -C 10 -loweralkyl, C 2 -C 10 -alkenyl, C 3 -C 10 -cycloalkyl, C 3 -C 10 -cycloalkenyl, C 3 -C 10 -bicycloalkenyl, aryl, aryl-C 1 -C 10 -alkyl, heterocyclic or heterocyclic-C 1 -C 10 -alkyl, each of which is optionally substituted with C 1 -C 10 -loweralkyl, halogen, hydroxy, aryl or heterocyclic; or (9) ═N--N(R 21 )(R 22 ) wherein R 21 and R 22 are independently selected from hydrogen, C 1 -C 10 -loweralkyl, aryl, aryl-C 1 -C 10 -alkyl, heterocyclic and heterocyclic-C 1 -C 10 -alkyl; R 8 is (1) --OC(O)N(OR 20 )(R 24 ) or (2) --O--C(O)--NHN(R 24 )(R 25 ) wherein R 20 is hydrogen, C 1 -C 10 -loweralkyl, C 2 -C 10 -alkenyl, C 3 -C 10 -cycloalkyl, C 3 -C 10 -cycloalkenyl, C 3 -C 10 -bicycloalkenyl, aryl or heterocyclic, each of which is optionally substituted with C 1 -C 10 -loweralkyl, hydroxy, aryl or heterocyclic and R 24 and R 25 are independently selected from (a) hydrogen, (b) C 1 -C 10 -loweralkyl, (c) C 2 -C 10 -alkenyl, (d) C 2 -C 10 -alkynyl, (e) C 3 -C 10 -cycloalkyl, (f) substituted C 1 -C 10 -loweralkyl, substituted C 2 -C 10 -alkenyl, substituted C 2 -C 10 -alkynyl or substituted C 3 -C 10 -cycloalkyl wherein the C 1 -C 10 -loweralkyl group, the C 2 -C 10 -alkenyl group, the C 2 -C 10 -alkynyl group or the C 3 -C 10 -cycloalkyl group is substituted by one or two substituents independently selected from (i) hydroxy, (ii) --COOH, (iii) --CN, (iv) --Q--C 1 -C 10 -loweralkyl, --Q-aryl, --Q-(aryl-C 1 -C 10 -alkyl), --Q-heterocyclic or --Q-(heterocyclicalkyl) wherein Q is --O--, --S--, --S(O)--, --S(O) 2 --, --C(O)--, --OC(O)--, --C(O)O--, --C(O)C(O)--O--, --O--C(O)C(O)--, --C(O)NH--, --NHC(O)--, --OC(O)NH--, --NHC(O)O--, --NH--C(O)--NH--, --S(O) 2 NH--, --NHS(O) 2 --, --N(R 27 )--, --C(NR 27 )NHNH-- and --NHNHC(NR 27 )-- wherein R 27 is hydrogen, C 1 -C 10 -loweralkyl, aryl or heterocyclic, (v) C 3 -C 10 -cycloalkyl, (vi) aryl, (vii) heterocyclic, (viii) --N(R 28 )(R 29 ) R 28 and R 29 are independently selected from hydrogen, C 1 -C 10 -loweralkyl, hydroxy-C 1 -C 10 -alkyl, aryl and heterocyclic, (ix) guanidino, (x) --S(O) 2 R 11 wherein R 11 is C 1 -C 10 -loweralkyl, aryl or aryl-C 1 -C 10 -alkyl, (xi) --OS(O) 2 R 11 wherein R 11 is defined as above, (xii) --SO 3 H, (xiii) --S(O) 2 NH 2 , (xiv) --SR 28 wherein R 28 is defined as above, (xv) halogen, (xvi) oxo and (xvii) epoxy; (g) aryl, (h) heterocyclic, (i) --NHC(O)--O--(C 1 -C 10 -loweralkyl), (j) --NHC(O)-aryl, (k) --NHC(O)-heterocyclic or (l) C 1 -C 10 -loweralkyl substituted by --OC(O)--R f wherein R f is C 3 -C 10 -carboxyalkyl or --N(R 24 )(R 25 ) taken together form a nitrogen-containing heterocyclic group, (3) --O(CH 2 ) i C(O)N(OR 24 )(R 25 ) wherein i, R 24 and R 25 are defined as above, (4) --O(CH 2 ) i C(O)N(R 24 )(N(R 24 )(R 25 )) wherein i, R 24 and R 25 are defined as above, (5) --O(CH 2 ) i NHC(O)N(R 24 )(R 25 ) wherein i, R 24 and R 25 are defined as above, (6) --(CH 2 ) i NHC(O)N(OR 24 )(R 25 ) wherein i, R 24 and R 25 are defined as above or (7) --(CH 2 ) i NHC(O)N(R 24 )(N(R 24 )(R 25 )) wherein i, R 24 and R 25 are defined as above; R 9 is hydrogen; R 10a is hydrogen and R 10b is hydrogen, hydroxy, protected hydroxy, C 1 -C 10 -alkoxy, C 2 -C 10 -alkenyl, C 2 -C 10 -alkenyloxy, halogen or --SR 28 wherein R 28 is independently defined as above or R 10b is hydrogen and R 10a is hydrogen, hydroxy, protected hydroxy, C 1 -C 10 -alkoxy, C 2 -C 10 -alkenyl, C 2 -C 10 -alkenyloxy, halogen or --SR 28 wherein R 28 is independently defined as above or R 10a and R 10b are both C 1 -C 10 -alkoxy or --SR 28a wherein R 28a is C 1 -C 10 -loweralkyl, aryl or heterocyclic or R 10a and R 10b taken together are oxo; and X is hydrogen and Y is hydrogen, hydroxy or protected hydroxy or Y is hydrogen and X is hydroxy or protected hydroxy or X and Y taken together are oxo wherein at each occurrence the term "aryl" is independently selected from phenyl, naphthyl, fluorenyl, (1,2,3,4-)-tetrahydronaphthyl, indenyl and indanyl which is either unsubstituted or substituted with one, two, or three substituents independently selected from the group consisting of C 1 -C 10 -loweralkyl, halo, halo-C 1 -C 10 -loweralkyl, halo-C 1 -C 10 -alkoxy, C 2 -C 10 -alkenyloxy, C 1 -C 10 -alkoxy, alkoxy-C 1 -C 10 -alkoxy, C 1 -C 10 -alkoxycarbonyl, C 1 -C 10 -alkoxycarbonylalkenyl, (C 1 -C 10 -alkoxycarbonyl)thio-C 1 -C 10 -alkoxy, thio-C 1 -C 10 -alkoxy, amino, C 1 -C 10 -alkylamino, C 1 -C 10 -dialkylamino, aminocarbonyl, aminocarbonyl-C 1 -C 10 -alkoxy, alkanoylamino, aryl-C 1 -C 10 -alkoxy, aryloxy, mercapto, nitro, carboxaldehyde, carboxy, carboxy-C 2 -C 10 -alkenyl, carboxy-C 1 -C 10 -alkoxy, C 1 -C 10 -alkylsulfonylamino, cyano-C 1 -C 10 -alkoxy, (heterocyclic)-C 1 -C 10 -alkoxy, hydroxy, hydroxy-C 1 -C 10 -alkoxy, phenyl, phenyl-substituted C 2 -C 10 -alkenyl, phenyl-substituted C 2 -C 10 -alkynyl, heterocyclic, --S(O) 2 NH 2 , tetrazolyl-C 1 -C 10 -alkoxy, tetrafluorophenyl and pentafluorophenyl and at each occurrence the term "heterocyclic" is independently selected from indolyl, quinolyl, isoquinolyl, tetrahydroquinolyl, benzofuryl, dihydrobenzofuryl, benzothienyl, azetidinyl, oxetanyl, pyrrolyl, pyrrolinyl, pyrrolidinyl, pyrazolyl, pyrazolinyl, pyrazolidinyl, imidazolyl, imidazolinyl, imidazolidinyl, pyridyl, piperidinyl, homopiperidinyl, pyrazinyl, piperazinyl, pyrimidinyl, pyridazinyl, oxazolyl, oxazolidinyl, isoxazolyl, isoxazolidinyl, morpholinyl, thiomorpholinyl, thiazolyl, thiazolidinyl, isothiazolyl, isothiazolidinyl, indolyl, quinolinyl, isoquinolinyl, benzimidazolyl, benzothiazolyl, benzoxazolyl, furyl, thienyl, thiazolidinyl, isothiazolyl, triazolyl, tetrazolyl, isoxazolyl, oxadiazolyl, thiadiazolyl, pyrrolyl, pyrimidyl, benzothienyl, compounds of the formula ##STR32## where X* is --CH 2 -- or --O-- and Y* is --C(O)-- or --C(R") 2 --! v where R" is hydrogen or C 1 -C 4 -alkyl and v is 1, 2 or 3, pyridin-2-on-1-yl, pyridin-4-on-1-yl, D-allose, D-altrose, D-glucose, D-mannose, D-gulose, D-idose, D-galactose, D-talose, D-ribose, D-arabinose, D-xylose, and D-lyxose wherein said heterocyclics are either unsubstituted or monosubstituted or disubstituted with substituents independently selected from hydroxy, halo, oxo (═O), amino, C 1 -C 10 -alkylamino, C 1 -C 10 -dialkylamino, C 1 -C 10 -alkoxy, alkoxy-C 1 -C 10 -alkoxy, alkoxy-C 1 -C 10 -alkyl, halo-C 1 -C 10 -alkyl, hydroxy, hydroxy-C 1 -C 10 -alkyl, C 3 -C 10 -cycloalkyl, aryl, aryl-C 1 -C 10 -alkyl, --COOH, --SO 3 H, --C(O)NH 2 and C 1 -C 10 -loweralkyl.
Claim 12
Independent Claim
1328 words
A method of immunomodulatory treatment comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compound having the formula: ##STR31## or a pharmaceutically acceptable salt, ester, amide or prodrug thereof wherein R 1 is hydrogen, a hydroxy protecting group, C 1 -C 10 -loweralkyl or phenyl-substituted C 1 -C 10 -loweralkyl; R 2 is hydrogen and R 3 is hydroxy or protected hydroxy or R 2 and R 3 taken together are oxo; R 4 is hydrogen or phenyl-substituted C 1 -C 10 -loweralkyl and R 5 is hydroxy or protected hydroxy or R 5 is hydrogen or phenyl-substituted C 1 -C 10 -loweralkyl and R 4 is hydroxy or protected hydroxy or R 4 and R 5 taken together are oxo; R 6 is hydrogen or phenyl-substituted C 1 -C 10 -loweralkyl and R 7 is hydrogen, hydroxy or protected hydroxy or R 7 is hydrogen or phenyl-substituted C 1 -C 10 -loweralkyl and R 6 is hydroxy or protected hydroxy or R 6 and R 7 taken together are (1) oxo, (2) diazo, (3) ═CH 2 (4) --O--(CH 2 ) 2 --O--, (5) --S--(CH 2 ) 2 --S--, (6) --O--(CH 2 ) 3 --O--, (7) --S--(CH 2 ) 3 --S--, (8) ═N--OR 20 wherein R 20 is hydrogen, C 1 -C 10 -loweralkyl, C 2 -C 10 -alkenyl, C 3 -C 10 -cycloalkyl, C 3 -C 10 -cycloalkenyl, C 3 -C 10 -bicycloalkenyl, aryl, aryl-C 1 -C 10 -alkyl, heterocyclic or heterocyclic-C 1 -C 10 -alkyl, each of which is optionally substituted with C 1 -C 10 -loweralkyl, halogen, hydroxy, aryl or heterocyclic; or (9) ═N--N(R 21 )(R 22 ) wherein R 21 and R 22 are independently selected from hydrogen, C 1 -C 10 -loweralkyl, aryl, aryl-C 1 -C 10 -alkyl, heterocyclic and heterocyclic-C 1 -C 10 -alkyl; R 8 is (1) --OC(O)N(OR 20 )(R 24 ) or (2) --O--C(O)--NHN(R 24 )(R 25 ) wherein R 20 is hydrogen, C 1 -C 10 -loweralkyl, C 2 -C 10 -alkenyl, C 3 -C 10 -cycloalkyl, C 3 -C 10 -cycloalkenyl, C 3 -C 10 -bicycloalkenyl, aryl or heterocyclic, each of which is optionally substituted with C 1 -C 10 -loweralkyl, hydroxy, aryl or heterocyclic and R 24 and R 25 are independently selected from (a) hydrogen, (b) C 1 -C 10 -loweralkyl, (c) C 2 -C 10 -alkenyl, (d) C 2 -C 10 -alkynyl, (e) C 3 -C 10 -cycloalkyl, (f) substituted C 1 -C 10 -loweralkyl, substituted C 2 -C 10 -alkenyl, substituted C 2 -C 10 -alkynyl or substituted C 3 -C 10 -cycloalkyl wherein the C 1 -C 10 -loweralkyl group, the C 2 -C 10 -alkenyl group, the C 2 -C 10 -alkynyl group or the C 3 -C 10 -cycloalkyl group is substituted by one or two substituents independently selected from (i) hydroxy, (ii) --COOH, (iii) --CN, (iv) --Q--C 1 -C 10 -loweralkyl, --Q-aryl, --Q-(aryl-C 1 -C 10 -alkyl), --Q-heterocyclic or --Q-(heterocyclicalkyl) wherein Q is --O--, --S--, --S(O)--, --S(O) 2 --, --C(O)--, --OC(O)--, --C(O)O--, --C(O)C(O)--O--, --O--C(O)C(O)--, --C(O)NH--, --NHC(O)--, --OC(O)NH--, --NHC(O)O--, --NH--C(O)--NH--, --S(O) 2 NH--, --NHS(O) 2 --, --N(R 27 )--, --C(NR 27 )NHNH-- and --NHNHC(NR 27 )-- wherein R 27 is hydrogen, C 1 -C 10 -loweralkyl, aryl or heterocyclic, (v) C 3 -C 10 -cycloalkyl, (vi) aryl, (vii) heterocyclic, (viii) --N(R 28 )(R 29 ) R 28 and R 29 are independently selected from hydrogen, C 1 -C 10 -loweralkyl, hydroxy-C 1 -C 10 -alkyl, aryl and heterocyclic, (ix) guanidino, (x) --S(O) 2 R 11 wherein R 11 is C 1 -C 10 -loweralkyl, aryl or aryl-C 1 -C 10 -alkyl, (xi) --OS(O) 2 R 11 wherein R 11 is defined as above, (xii) --SO 3 H, (xiii) --S(O) 2 NH 2 , (xiv) --SR 28 wherein R 28 is defined as above, (xv) halogen, (xvi) oxo and (xvii) epoxy; (g) aryl, (h) heterocyclic, (i) --NHC(O)--O--(C 1 -C 10 -loweralkyl), (j) --NHC(O)-aryl, (k) --NHC(O)-heterocyclic or (l) C 1 -C 10 -loweralkyl substituted by --OC(O)--R f wherein R f is C 3 -C 10 -carboxyalkyl or --N(R 24 )(R 25 ) taken together form a nitrogen-containing heterocyclic group, (3) --O(CH 2 ) i C(O)N(OR 24 )(R 25 ) wherein i, R 24 and R 25 are defined as above, (4) --O(CH 2 ) i C(O)N(R 24 )(N(R 24 )(R 25 )) wherein i, R 24 and R 25 are defined as above, (5) --O(CH 2 ) i NHC(O)N(R 24 )(R 25 ) wherein i, R 24 and R 25 are defined as above, (6) --(CH 2 ) i NHC(O)N(OR 24 )(R 25 ) wherein i, R 24 and R 25 are defined as above or (7) --(CH 2 ) i NHC(O)N(R 24 )(N(R 24 )(R 25 )) wherein i, R 24 and R 25 are defined as above; R 9 is hydrogen; R 10a is hydrogen and R 10b is hydrogen, hydroxy, protected hydroxy, C 1 -C 10 -alkoxy, C 2 -C 10 -alkenyl, C 2 -C 10 -alkenyloxy, halogen or --SR 28 wherein R 28 is independently defined as above or R 10b is hydrogen and R 10a is hydrogen, hydroxy, protected hydroxy, C 1 -C 10 -alkoxy, C 2 -C 10 -alkenyl, C 2 -C 10 -alkenyloxy, halogen or --SR 28 wherein R 28 is independently defined as above or R 10a and R 10b are both C 1 -C 10 -alkoxy or --SR 28a wherein R 28a is C 1 -C 10 -loweralkyl, aryl or heterocyclic or R 10a and R 10b taken together are oxo; and X is hydrogen and Y is hydrogen, hydroxy or protected hydroxy or Y is hydrogen and X is hydroxy or protected hydroxy or X and Y taken together are oxo wherein at each occurrence the term "aryl" is independently selected from phenyl, naphthyl, fluorenyl, (1,2,3,4-)-tetrahydronaphthyl, indenyl and indanyl which is either unsubstituted or substituted with one, two, or three substituents independently selected from the group consisting of C 1 -C 10 -loweralkyl, halo, halo-C 1 -C 10 -loweralkyl, halo-C 1 -C 10 -alkoxy, C 2 -C 10 -alkenyloxy, C 1 -C 10 -alkoxy, alkoxy-C 1 -C 10 -alkoxy, C 1 -C 10 -alkoxycarbonyl, C 1 -C 10 -alkoxycarbonylalkenyl, (C 1 -C 10 -alkoxycarbonyl)thio-C 1 -C 10 -alkoxy, thio-C 1 -C 10 -alkoxy, amino, C 1 -C 10 -alkylamino, C 1 -C 10 -dialkylamino, aminocarbonyl, aminocarbonyl-C 1 -C 10 -alkoxy, alkanoylamino, aryl-C 1 -C 10 -alkoxy, aryloxy, mercapto, nitro, carboxaldehyde, carboxy, carboxy-C 2 -C 10 -alkenyl, carboxy-C 1 -C 10 -alkoxy, C 1 -C 10 -alkylsulfonylamino, cyano-C 1 -C 10 -alkoxy, (heterocyclic)-C 1 -C 10 -alkoxy, hydroxy, hydroxy-C 1 -C 10 -alkoxy, phenyl, phenyl-substituted C 2 -C 10 -alkenyl, phenyl-substituted C 2 -C 10 -alkynyl, heterocyclic, --S(O) 2 NH 2 , tetrazolyl-C 1 -C 10 -alkoxy, tetrafluorophenyl and pentafluorophenyl and at each occurrence the term "heterocyclic" is independently selected from indolyl, quinolyl, isoquinolyl, tetrahydroquinolyl, benzofuryl, dihydrobenzofuryl, benzothienyl, azetidinyl, oxetanyl, pyrrolyl, pyrrolinyl, pyrrolidinyl, pyrazolyl, pyrazolinyl, pyrazolidinyl, imidazolyl, imidazolinyl, imidazolidinyl, pyridyl, piperidinyl, homopiperidinyl, pyrazinyl, piperazinyl, pyrimidinyl, pyridazinyl, oxazolyl, oxazolidinyl, isoxazolyl, isoxazolidinyl, morpholinyl, thiomorpholinyl, thiazolyl, thiazolidinyl, isothiazolyl, isothiazolidinyl, indolyl, quinolinyl, isoquinolinyl, benzimidazolyl, benzothiazolyl, benzoxazolyl, furyl, thienyl, thiazolidinyl, isothiazolyl, triazolyl, tetrazolyl, isoxazolyl, oxadiazolyl, thiadiazolyl, pyrrolyl, pyrimidyl, benzothienyl, compounds of the formula ##STR32## where X* is --CH 2 -- or --O-- and Y* is --C(O)-- or --C(R") 2 --! v where R" is hydrogen or C 1 -C 4 -alkyl and v is 1, 2 or 3, pyridin-2-on-1-yl, pyridin-4-on-1-yl, D-allose, D-altrose, D-glucose, D-mannose, D-gulose, D-idose, D-galactose, D-talose, D-ribose, D-arabinose, D-xylose, and D-lyxose wherein said heterocyclics are either unsubstituted or monosubstituted or disubstituted with substituents independently selected from hydroxy, halo, oxo (═O), amino, C 1 -C 10 -alkylamino, C 1 -C 10 -dialkylamino, C 1 -C 10 -alkoxy, alkoxy-C 1 -C 10 -alkoxy, alkoxy-C 1 -C 10 -alkyl, halo-C 1 -C 10 -alkyl, hydroxy, hydroxy-C 1 -C 10 -alkyl, C 3 -C 10 -cycloalkyl, aryl, aryl-C 1 -C 10 -alkyl, --COOH, --SO 3 H, --C(O)NH 2 and C 1 -C 10 -loweralkyl.
References Cited (Backward Citations)
US3929992A
Cited
US3993749A
Cited
US5206018A
Cited
EP0429436A2
Cited
US5023264A
Cited
EP0467606A1
Cited
EP0470804A1
Cited
WO1992005179A1
Cited
US5221670A
Cited
US5233036A
Cited
US5120842B1
Cited
EP0507556A1
Cited
US5120842A
Cited
US5100883A
Cited
US5118678A
Cited
EP0509795A2
Cited
US5102876A
Cited
US5118677A
Cited
EP0515140A1
Cited
WO1992021341A1
Cited
EP0525960A1
Cited
US5202332A
Cited
US5457111A
Cited
EP0533433A1
Cited
US5151413A
Cited
WO1993011130A1
Cited
EP0551182A1
Cited
WO1993016189A1
Cited
US5194447A
Cited
US5262424A
Cited
US5177203A
Cited
WO1993018043A1
Cited
US5346893A
Cited
US5260299A
Cited
EP0562853A1
Cited
WO1993019763A1
Cited
EP0568310A1
Cited
WO1994002485A1
Cited
WO1994002136A1
Cited
WO1994002137A1
Cited
WO1994004540A1
Cited
US5302600A
Cited
US5256790A
Cited
WO1994009010A1
Cited
US5302584A
Cited
EP0593227A1
Cited
US5262423A
Cited
WO1994010176A1
Cited
US5258389A
Cited
US5260300A
Cited
WO1994011380A1
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 2000-09-29 | 2001-03-31 | 2001-09-30 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2004-09-29 | 2005-03-31 | 2005-09-30 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2008-09-29 | 2009-03-31 | 2009-09-30 | $7700.00 | Window Closed / Lapsed |